



UNIVERSIDADE
ESTADUAL DE LONDRINA

JULIANO YASUO ODA

**TRATAMENTO COM BAIXAS DOSES DE ASPIRINA NAS
FASES AGUDA E CRÔNICA DA INFECÇÃO MURINA POR
Trypanosoma cruzi PROMOVE NEUROPROTEÇÃO
ENTÉRICA**

JULIANO YASUO ODA

**TRATAMENTO COM BAIXAS DOSES DE ASPIRINA NAS
FASES AGUDA E CRÔNICA DA INFECÇÃO MURINA POR
Trypanosoma cruzi PROMOVE NEUROPROTEÇÃO
ENTÉRICA**

Tese apresentada ao Programa de Pós-Graduação em Patologia Experimental da Universidade Estadual de Londrina, como requisito parcial para obtenção do título de Doutor.

Orientador: Prof. Dr. Eduardo José de Almeida Araújo.

Coorientador: Prof. Dr. Phileo Pinge Filho.

Londrina
2016

Ficha de identificação da obra elaborada pelo autor, através do Programa de Geração Automática do Sistema de Bibliotecas da UEL

Oda, Juliano Yasuo.

Tratamento com baixas doses de aspirina nas fases aguda e crônica da infecção murina por trypanosoma cruzi promove neuroproteção entérica / Juliano Yasuo Oda. - Londrina, 2016.
92 f. : il.

Orientador: Eduardo José de Almeida Araújo.

Coorientador: Phileo Pinge Filho.

Tese (Doutorado em Patologia Experimental) - Universidade Estadual de Londrina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Patologia Experimental, 2016.

Inclui bibliografia.

1. Doença de Chagas - Teses. 2. Neuropatia entérica - Teses. 3. Neurônios mientéricos - Teses. 4. Aspirina - Teses. I. Araújo, Eduardo José de Almeida. II. Pinge Filho, Phileo. III. Universidade Estadual de Londrina. Centro de Ciências Biológicas. Programa de Pós-Graduação em Patologia Experimental. IV. Título.

JULIANO YASUO ODA

**TRATAMENTO COM BAIXAS DOSES DE ASPIRINA NAS FASES
AGUDA E CRÔNICA DA INFECÇÃO MURINA POR *Trypanosoma
cruzi* PROMOVE NEUROPROTEÇÃO ENTÉRICA**

Tese apresentada ao Programa de Pós-Graduação em Patologia Experimental da Universidade Estadual de Londrina, como requisito parcial para obtenção do título de Doutor.

BANCA EXAMINADORA

Orientador: Prof. Dr. Eduardo José de Almeida
Araújo
Universidade Estadual de Londrina - UEL

Profa. Dra. Débora de Mello Gonçalves
Sant'Ana
Universidade Estadual de Maringá - UEM

Profa. Dra. Glaucia Scantamburlo A. Fernandes
Universidade Estadual de Londrina - UEL

Profa. Dra. Graziela Sciantti Ceravolo
Universidade Estadual de Londrina - UEL

Prof. Dr. Wander Rogério Pavanelli
Universidade Estadual de Londrina - UEL

Londrina, 27 de julho de 2018.

Dedico este trabalho a minha família em especial minha esposa Thais Tatiana Pfau e meus filhos Luiz Eduardo Y. Oda e Miguel Augusto S. Oda.

AGRADECIMENTOS

A Deus por conceder-me força, perseverança e lucidez em meio às dificuldades.

A minha esposa Thais Tatiana Pfau e meus filhos Luiz Eduardo Y. Oda e Miguel Augusto S. Oda que concederam o apoio emocional e incentivo para concluir esta etapa e por compreenderem minha ausência em muitos momentos importantes de nossa vida.

Aos meus pais, em especial minha mãe Amélia Oda (*in memorian*) que sempre esteve ao meu lado e acreditou no meu potencial, meu pai Tetsuya Oda (*in memorian*), obrigado por ajudarem a ser quem sou.

Ao meu orientador e amigo prof. Eduardo José de Almeida Araújo, pelos ensinamentos, não apenas metodológicos, mas ensinamento para a vida. Agradeço pela paciência e compreensão nos momentos de dificuldade pelo qual passei e, principalmente, por acreditar em mim e em nosso projeto, sempre serei grato por sua atitude.

Ao meu Coorientador prof. Phileno Pinge Filho, pelos ensinamentos e discussões que contribuíram para o desenvolvimento do trabalho.

A minha família, meus irmãos, e sobrinhos que estiveram ao meu lado e torceram para que obtivesse sucesso nessa jornada.

À família Pfau, em especial Luiz Augusto Pfau e Fátima Lúcia Pfau que me adotaram e ajudaram-me a trilhar essa caminhada, meu muito obrigado.

A minha amiga Mônica Belém, pela amizade pura e verdadeira, os momentos de descontração e discussão e, principalmente, por me acompanhar em todas as etapas deste longo projeto, meu muito obrigado.

Ao amigo e irmão Marco Antonio Santana Castilho, por sua amizade sincera, pelos momentos de discussão, apoio emocional e incentivo, meu muito obrigado.

Aos Amigos da pós-graduação e que se tornaram amigos para a vida, Bruno Luchetti, Andréia Pupim, Paulo Botura, obrigado pelo acolhimento e companheirismo.

A todos que participaram do projeto Neide Moreira, Cristina Massocatto, Evandro Beraldi, Thalita Massi, Rafael Gouveia e todos os alunos de IC, que acreditaram na possibilidade de realizar um bom trabalho apesar das inúmeras dificuldades, meus sinceros agradecimentos.

Aos colegas do laboratório de Neurociência Entérica/UEL.

Aos colegas do programa de Pós-Graduação em Patologia Experimental pelos momentos de discussão e o acolhimento.

Aos Professores do Programa de Pós-Graduação em Patologia Experimental, por compartilharem do conhecimento e estimularem em nós o senso crítico e o desejo pelo conhecimento.

Aos professores Wander Pavanelli e Débora Sant'Ana membros da banca de qualificação pela valorosa contribuição na correção da tese.

Aos funcionários e técnicos dos laboratórios envolvidos em especial ao sr. Sérgio Camargo Sisti pelo auxílio prestado.

À UFMS – Universidade Federal de Mato Grosso do Sul, que me concedeu a licença para cursar a Pós-Graduação, meu muito obrigado.

À Fundação Araucária, pelo incentivo financeiro ao projeto realizado.

A todos que de uma forma direta ou indireta contribuíram para que este trabalho se tornasse uma realidade.

**Combati o bom combate,
Acabei a carreira,
Guardei a fé**

(II Timóteo 4:7)

ODA, JULIANO YASUO. **Tratamento com baixas doses de aspirina nas fases aguda e crônica da infecção murina por *trypanosoma cruzi* promove neuroproteção entérica.** 2016. 90 f. Tese (Doutorado em Patologia Experimental) – Universidade Estadual de Londrina, Londrina, 2016.

RESUMO

A doença de Chagas (DC) representa um importante problema de saúde pública no Brasil, devido ao surgimento de novos casos e também por ainda não possuir cura. A DC acomete o controle nervoso do trato gastrointestinal, resultando em severos distúrbios de motilidade. Essas alterações de motilidade devem-se, principalmente, à perda de neurônios do plexo mientérico, o qual é um dos plexos ganglionados do sistema nervoso entérico. Neste estudo, objetivou-se avaliar se o uso de baixas doses de aspirina (ASA) durante a fase aguda (20 mg/kg) ou crônica (50 mg/kg) da infecção experimental por *T. cruzi* seria capaz de proteger neurônios mientéricos do cólon de camundongos. Todos os procedimentos foram aprovados pela Comissão de Ética no Uso de Animais da Universidade Estadual de Londrina (UEL). Camundongos Swiss foram distribuídos em grupos que receberam PBS ou foram tratados com baixas doses de aspirina durante a fase aguda (20 mg/Kg, ASA_{Early}) ou crônica (50 mg/Kg, ASA_{Delayed}) da infecção causada pela cepa Y de *T. cruzi*. Após 75 dias de infecção, coletou-se o cólon para quantificar focos inflamatórios em cortes histológicos e neurônios mientéricos gerais, nitrérgicos, VIPérgicos e colinérgicos evidenciados por imunofluorescência. Além disso, avaliou-se o trânsito gastrointestinal. Contou-se o número total de corpos celulares de neurônios gerais, nitrérgicos e VIPérgicos presentes em 24,06 mm² de cada animal, valor que projetado para 1 cm². O número de neurônios colinérgicos foi estimado pela diferença entre o número de neurônios gerais e o número de neurônios nitrérgicos. Foi também realizada a mensuração da área do corpo celular de 300 neurônios evidenciados em cada marcação de cada animal. Foram mensuradas 700 varicosidades nervosas mientéricas VIPérgicas e contendo Substância P. O tempo de trânsito intestinal foi avaliado com a administração de um marcador não absorvível, via gavagem (tempo zero), até a eliminação do primeiro pelete de fezes na cor vermelha. Os dados foram expressos por média ± desvio padrão, e os grupos foram comparados utilizando ANOVA, seguido pelo pós-teste de Tukey, considerando significativo $p < 0,05$. O tratamento com ASA na fase aguda provocou uma significativa redução no pico de parasitemia ($p < 0,05$). Com relação a quantidade de foco inflamatório, ambos tratamentos foram eficientes para reduzi-los. Os camundongos infectados do grupo PBS apresentaram intensa perda neuronal mientérica, tanto na população geral (60,67%), como também nas subpopulações nitrérgica (49,0%), colinérgica (67%) e VIPérgica (38,0%) ($p < 0,05$). Essa morte de neurônios foi significativamente reduzida pelo tratamento com ASA tanto na fase aguda (ASA_{Early}) como na fase crônica (ASA_{Delayed}) da infecção ($p < 0,05$). A intensa morte de neurônios colinérgicos nos animais do PBS provocou significativo retardo do trânsito do tubo digestório ($p < 0,05$). O tratamento com ASA contribuiu para que o tempo de trânsito gastrointestinal dos animais infectados permanecesse semelhantes aos animais saudáveis. A infecção por *T. cruzi*, provocou uma hipertrofia no corpo celular dos neurônios remanescentes. O tratamento com ASA na fase aguda da infecção contribuiu de forma mais expressiva para manutenção da

área do corpo celular dos neurônios mientéricos remanescentes. Camundongos infectados com *T. cruzi* não tratados com ASA apresentaram varicosidades nervosas mientéricas VIPérgicas atrofiadas e as contendo substância P estavam hipertrofiadas. Além disso, as fibras nervosas apresentaram maior intensidade de brilho para SP. Conclui-se que a administração de ASA apresentou efeito neuroprotetor para os neurônios do plexo mientérico do cólon de camundongos infectados por *T. cruzi*.

Palavras-Chave: Doença de Chagas. Neuropatia Entérica. Aspirina. Neurônios mientéricos.

ODA, JULIANO YASUO. **Treatment with low doses of aspirin in acute and chronic phases of murine infection by *Trypanosoma cruzi* promotes enteric neuroprotection.** 2016. 90 p. Thesis (Doctoral Degree in Experimental Pathology) – Universidade Estadual de Londrina, Londrina, 2016.

ABSTRACT

Chagas disease (DC) represents an important public health problem in Brazil, due to the emergence of new cases and still has no cure. The DC affects the nervous control of the gastrointestinal tract, resulting in severe disorders of motility. These alterations of motility are due, mainly, to the loss of neurons of the myenteric Plexus, which is one of the ganglionated Plexus of the enteric nervous system. In this study, the objective to assess whether the use of low-dose aspirin (ASA) during the acute phase (20 mg/kg) or chronic (50 mg/kg) of the experimental infection by *t. cruzi* would be able to protect myenteric neurons of the mice colon. All procedures were approved by the Ethics Committee on use of Animals at the State University of Londrina (UEL). Swiss mice were divided into groups that received PBS or were treated with low doses of aspirin during the acute phase (20 mg/Kg, ASA_{Early}) or chronic (50 mg/Kg, ASA_{Delayed}) of the infection caused by the Y strain of *t. cruzi*. After 75 days of infection, collected the colon to quantify inflammatory focus in histological sections and general myenteric neurons, nitrergic, VIPergic and cholinergic evidenced by immunofluorescence. In addition, assessed the gastrointestinal transit. The total number of cell bodies of general neurons, nitrergic and VIPergic present in 24.06 mm² of each animal was counted, which designed for 1 cm². The number of cholinergic neurons was estimated by the difference between the number of general neurons and the number of nitrergic neurons. The measurement was performed in the area of the cell body of neurons identified 300 in each marking of each animal. Were measured 700 VIPergic myenteric nerve varicosities and containing Substance P. The intestinal transit time was evaluated with the administration of a nonabsorbable marker, gavage pathway (zero time), until the removal of the first pellet of stool in red color. The data were expressed by mean \pm standard deviation, and the groups were compared using ANOVA, followed by the Tukey post-test, considering significant $p < 0.05$. The ASA during the acute phase treatment caused a significant reduction in peak parasitaemia ($p < 0.05$). Regarding the amount of inflammatory focus, both treatments were efficient to reduce them. The mice infected PBS group showed intense myenteric neuronal loss, both in the general population as well as in subpopulations (60.67%), nitrergic (49.0%), cholinergic (67%) and VIPergic (38.0%) ($p < 0.05$). This death of neurons was significantly reduced by treatment with ASA both in the acute phase (ASA_{Early}) as in the chronic phase (ASA_{Delayed}) of the infection ($p < 0.05$). The intense death of cholinergic neurons in animals of the PBS caused significant traffic delay of the digestive tube ($p < 0.05$). Treatment with ASA contributed to the gastrointestinal transit time of infected animals remain similar to healthy animals. Infection with *t. cruzi*, provoked a hypertrophy in the cell body of neurons. Treatment with ASA in the acute phase of the infection contributed more expressive for maintenance of the cell body of myenteric neurons remaining. Mice infected with *t. cruzi* treated with ASA presented VIPergic myenteric nerve varicosities atrophied and the containing substance P were hypertrophied. In addition, the nerve fibers showed greater intensity of brightness to SP. Concluded

that the wing administration presented a neuroprotective effect to neurons of the myenteric plexus of the mice colon infected by *t. cruzi*.

Keywords: Chagas disease. Enteric Neuropathy. Aspirin. Myenteric Neurons.

LISTA DE ILUSTRAÇÕES

Figura 1 – Rotas de migração da América Latina e estimativa do número total de infectados em países não-endêmicos	18
Figura 2 – Transmissão vetorial e ciclo de vida do <i>T. cruzi</i>	19
Figura 3 – (A) Desenho esquemático dos plexos ganglionados do sistema nervoso entérico (Adaptado de Brehmer, 2006). (B) Organização do plexo mioentérico de humanos e mamíferos médios e grandes (Adaptado de Furness, 2006)	29

ARTIGO

Figure 1. Flowchart showing the method used in the study. (A) Experimental groups, (B) Aspirin (ASA) treatment protocol performed during the acute phase (ASA _{Early}) of infection with <i>Trypanosoma cruzi</i> , (C) ASA treatment protocol performed during the chronic phase (ASA _{Delayed}) of infection with <i>T. cruzi</i> , and (D) Parasitemia curve for male Swiss mice infected with <i>T. cruzi</i> (Y strain) and treated with ASA during the acute phase (ASA _{Early}) of the infection. *p < 0.05 compared to the infected group (Mann-Whitney's test)	60
Figure 2. Evaluation of inflammatory infiltrate in uninfected mice, mice infected with <i>Trypanosoma cruzi</i> (Y strain) and treated with aspirin (ASA). (A) Quantification of inflammatory infiltrate present on the colonic wall after histopathological analysis, (B) Photomicrography showing absence of inflammatory foci in uninfected mice, (C) Intense inflammatory foci presence (see arrow head) in PBS-treated-mice infected with <i>T. cruzi</i> , (D) Reduction of inflammatory foci (see arrow head) ASA _{Early} -treated-mice infected with <i>T. cruzi</i> , (E) Reduction of inflammatory foci (see arrow head) in ASA _{Delayed} -treated-mice infected with <i>T. cruzi</i> . # p < 0.05 compared to uninfected PBS-treated-group. *p < 0.05 compared to infected PBS-treated-group. ANOVA one-way, followed by Tukey's post-test	61
Figura 3. Morphoquantitative and morphometric evaluation of myosin-V ⁺ myenteric neurons of uninfected mice, mice infected with	

Trypanosoma cruzi (Y strain) and mice treated with aspirin (ASA). (A) General myenteric neuronal population density (myosin- V⁺), (B) Cell body area of the general myenteric neuronal population, (C) to (F) Immunofluorescence photomicrographies showing myenteric neurons (see arrow heads) in the colon of uninfected mice, infected with *T. cruzi* (Y strain) and treated with ASA during the acute (ASA_{Early}) or chronic (ASA_{Delayed}) phases of the infection. #p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. †p < 0.05 compared to uninfected ASA-treated-groups. ‡p < 0.05 compared to infected ASA-treated-groups. †p < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test62

Figura 4. Morphoquantitative and morphometric evaluation of nitrergic myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) Nitrergic myenteric neuronal population density, (B) Cell body area of the nitrergic myenteric neuronal population, (C) to (F) Immunofluorescence photomicrographies showing myenteric neurons (see arrow heads) in the colon of uninfected mice, infected with *T. cruzi* (Y strain) and treated with ASA during the acute (ASA_{Early}) or chronic (ASA_{Delayed}) phases of the infection. #p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. †p < 0.05 compared to uninfected ASA-treated-groups. ‡p < 0.05 compared to infected ASA-treated-groups. †p < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test63

Figura 5. Morphoquantitative and morphometric evaluation of VIPergic myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) VIPergic myenteric neuronal population density, (B) Cell body area of the VIPergic myenteric neuronal population, (C) to (F) Immunofluorescence photomicrographies showing myenteric

neurons (see arrow heads) in the colon of uninfected mice, infected with *T. cruzi* (Y strain) and treated with ASA during the acute (ASA_{Early}) or chronic (ASA_{Delayed}) phases of the infection. #p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. †p < 0.05 compared to uninfected ASA-treated-groups. ‡p < 0.05 compared to infected ASA-treated-groups. †p < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test64

Figura 6. Morphoquantitative, morphometric, and physiological evaluation of myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) Cholinergic myenteric neuron population density, (B) Gastrointestinal transit evaluation, (C) to (D) Varicosities area of VIP and substance P (SP) producing nerve fibers, (E) Bright field intensity of varicosities containing SP. #p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. †p < 0.05 compared to uninfected ASA-treated-groups. ‡p < 0.05 compared to infected ASA-treated-groups. †p < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test65

LISTA DE TABELAS

Tabela 1 – Fatores de virulência expressados pelo *T. cruzi* durante sua interação com a célula hospedeira21

ARTIGO

Tabela 1. Primary and secondary antibodies used for the immunofluorescence technique.....59

LISTA DE ABREVIATURAS E SIGLAS

AINES	Anti-inflamatórios não Esteroidais
ASA	Aspirina
BSA	Albumina Bovina Sérica
°C	Graus Celcius
CEUA/UEL	Comissão de Ética no Uso de Animais da Universidade Estadual de Londrina
COX-1	Ciclooxigenase 1
COX-2	Ciclooxigenase 2
DATASUS	Departamento de Informática do Sistema Único de Saúde
DC	Doença de Chagas
DPI	Dias Pós-Infecção
HE	Hematoxilina e Eosina
iNOS	Oxido Nítrico Sintase Induzida
MHC	Complexo Principal de Histocompatibilidade
µL	Microlitro
µm	Micrômetro
MS	Ministério da Saúde
nNOS	Óxido Nítrico Sintase Neuronal
NO	Óxido Nítrico
PBS	Tampão Fosfato-salino
PCR	Reação de cadeia da polimerase
PGE2	Prostaglandina E2
pH	Potencial hidrogeniônico
SNC	Sistema Nervoso Central
SNE	Sistema Nervoso Entérico

SIM	Sistema Informatizado de Mortalidade
SP	Substância P
SUS	Sistema Único de saúde
<i>T. cruzi</i>	<i>Trypanosoma cruzi</i>
VIP	Peptídeo Vasoativo Intestinal

SUMÁRIO

1	INTRODUÇÃO	16
1.1	<i>Doença de Chagas</i>	16
1.2	<i>Interação Parasito X Hospedeiro</i>	18
1.3	<i>Manifestações Clínicas da Doença de Chagas</i>	24
1.4	<i>Neuropatia Entérica Chagásica</i>	28
1.5	<i>Tratamento Farmacológico da Doença de Chagas</i>	32
2	OBJETIVO	37
2.1	OBJETIVO GERAL	37
2.1.1	Objetivos Específicos	37
 ARTIGO CIENTÍFICO – MYENTERIC NEUROPROTECTIVE ROLE OF ASPIRIN IN ACUTE AND CHRONIC EXPERIMENTAL INFECTIONS WITH <i>Trypanosoma cruzi</i>		38
 CONCLUSÃO		66
 REFERÊNCIAS		67
 ANEXOS		79
ANEXO A – Certificado de aprovação comitê de ética.....		80
ANEXO B – Certificado de Submissão do manuscrito		81
ANEXO C – Normas do periódico Neurogastroenterology & Motility.....		82

1. INTRODUÇÃO

1.1 Doença de Chagas

A descoberta da tripanossomíase humana por Carlos Chagas (DC) em 1909 foi um dos trabalhos mais completos e bem-sucedidos na história da medicina tropical. Carlos Chagas não apenas descobriu uma doença nova, mas primeiramente descreveu com riqueza de detalhes não apenas um novo parasito, mas seu ciclo de transmissão, seu vetor e reservatório mamífero intermediário, bem como as manifestações clínicas agudas do primeiro caso a acometer humanos (COURA e BORGES-PEREIRA, 2010; RASSI-Jr, RASSI e MARIN-NETO, 2010).

A história natural da DC começou há milhões de anos como uma doença enzoótica entre os animais selvagens, e isso ainda persiste em áreas enzoóticas, tais como a região amazônica. Devido ao extenso desmatamento para agricultura e criação de gado ao longo dos últimos 200-300 anos na América Latina, triatomíneos que ficaram sem suas fontes de alimentos devido à remoção de animais selvagens começaram a colonizar áreas circundantes habitações humanas, e as próprias habitações. Eles se adaptaram a este novo nicho, alimentando-se do sangue de humanos e animais domésticos (COURA e BORGES-PEREIRA, 2010; RASSI Jr, RASSI e REZENDE, 2012).

A DC é a manifestação clínica causada pelo protozoário *Trypanosoma cruzi* e a transmissão pode ocorrer de forma vetorial, congênita, oral, por transfusões sanguíneas e transplantes de órgãos. Atualmente é reconhecida pela Organização Mundial da Saúde como sendo a 13ª doença tropical mais negligenciada e representa um importante problema social e econômico na América Latina, haja vista que ainda não há um tratamento que promova a cura dessa enfermidade (COURA; DIAS, 2009; RASSI-Jr, RASSI e MARIN-NETO, 2010; BRASIL, 2010).


Essa doença é amplamente dispersa, principalmente, na América Latina, onde se estima que existam 7 milhões de pessoas infectadas e a cada ano são relatados cerca de 50 mil novos casos, sendo que aproximadamente 75 a 90 milhões de pessoas estejam sob risco potencial de se tornarem infectadas (COURA; DIAS, 2009; MAYA, et al., 2010; MUKHERJEE, et al., 2011; MOREIRA, et al., 2011; WHO 2014).

No Brasil, em virtude da implementação de medidas de controle na transmissão vetorial e transfusional, ocorreu um decréscimo significativo no surgimento de novos casos de DC. No entanto, dados epidemiológicos dos últimos dez anos apontam para a continuidade dos números de casos de DC. Nos anos de 2000 a 2010 foram registrados 1.093 casos de DC aguda no Brasil, sendo que a maior parte (71%) ocorreu por transmissão oral devido à ingestão de alimentos contaminados (caldo de cana, açaí, entre outros). Mas, no Brasil predominam os casos crônicos de DC, decorrentes de infecções adquiridas no passado, com aproximadamente três milhões de indivíduos infectados representando um alto custo para o serviço de saúde, tendo em vista a sua característica de uma longa cronicidade (MEDEI et al., 2008; COURA; DIAS, 2009; BRASIL, 2011; MARTINS-MELO, et al., 2012).

Essa doença representa a quarta causa de morte entre as doenças infecto-parasitárias, considerando a faixa etária acima de 45 anos. Martins-Melo et al. (2012), analisando os óbitos registrados no período entre 1979 a 2009 cadastrados no Sistema de Informação de Mortalidade SIM/MS/DATASUS, verificaram que de um total de 27 milhões de óbitos registrados no Brasil a DC foi mencionada como a causa de morte em mais de 172 mil (0,62%) registros (MEDEI et al., 2008; ANDREOLLO; MALAFAIA, 2009; MAYA, et al., 2010; BRASIL, 2010).

A DC está emergindo na América do Norte (Figura 1), provavelmente a partir da migração de indivíduos infectados (COURA e VIÑA, 2010; EPTING, COATES e ENGMAN, 2010). Dessa forma, o Centro de controle de doenças e prevenção estima que mais de 300 mil pessoas estejam infectadas com *T. cruzi* e que um total de 30 a 45 mil pessoas provavelmente serão diagnosticadas com cardiopatia chagásica grave e, aproximadamente 3 a 5 mil desenvolverão a forma digestiva da DC. Assim, são necessárias medidas como aprimorar os métodos de diagnóstico e alternativas terapêuticas para possibilitar uma melhor assistência ao paciente, bem como investimento para prevenir novas infecções (BERN e MONTGOMERY, 2009; NUNES et al., 2013; MONTGOMERY, et al., 2014).

Figura 1 – Rotas de migração da América Latina e estimativa do número total de infectados em países não-endêmicos




Fonte: (COURA e VIÑA, 2010).

1.2 Interação Parasito X Hospedeiro

O ciclo de vida do *T. cruzi* é complexo, com diferentes estágios de desenvolvimento no inseto vetor e no hospedeiro mamífero (Figura 2). As formas típicas no hospedeiro mamífero são a tripomastigota não-replicativa e a amastigota (intracelular replicativa), enquanto as formas epimastigota e tripomastigota metacíclica (infectante) são encontradas no hospedeiro invertebrado (BRENER, 1971; RASSI-Jr, RASSI e MARIN-NETO, 2010).

Figura 2 – Transmissão vetorial e ciclo de vida do *T. cruzi*.



Fontes: (Adaptado de RASSI Jr, RASSI e MARIN-NETO, 2010).

Como parte de seu ciclo evolutivo, o *T. cruzi* um parasito intracelular obrigatório, apresenta-se sob três formas evolutivas diferentes: tripomastigota, epimastigota e amastigota. A diferenciação ocorre como forma adaptativa necessária para o desenvolvimento nos dois hospedeiros: o invertebrado (triatomíneo hematófago) e o vertebrado (mamíferos, incluindo o homem) (COURA e BORGES-PEREIRA, 2010; RASSI-Jr, RASSI e MARIN-NETO, 2010; SOUZA, CARVALHO e BARRIAS, 2010; BARRIAS, CARVALHO e SOUZA, 2013).

Portanto, durante a fase aguda, as formas infectantes do *T. cruzi* (amastigotas e tripomastigotas) são hábeis para infectar todas as células nucleadas do hospedeiro mamífero devido a um complexo mecanismo de invasão celular. A forma tripomastigota metacíclica invade principalmente macrófagos, fibroblastos e outros tecidos mesenquimais no sítio primário da infecção. Após a transformação na forma

tripomastigota sanguínea, o parasito precisa resistir a resposta imune humoral mediada pelo complemento e para iniciar o novo ciclo de vida, o parasito precisa invadir novas células (SOUZA, CARVALHO e BARRIAS, 2010; TEIXEIRA et al., 2011; OSORIO et al., 2012).

O fato do *T. cruzi* possuir a capacidade de infectar célula nucleada *in vitro* e infectam músculo estriado, músculo cardíaco e neurônios entéricos, leva os pesquisadores a inferir um possível e intrínseco tropismo celular. Demonstra ainda perfil geográfico restrito, levando a hipótese de que existe uma relação entre determinada cepa de *T. cruzi* e seu tropismo tecidual e clones de cepas distintas podem ser isoladas de pacientes com a forma cardíaca ou gastrintestinal da doença (MELO e BRENER, 1978; EPTING, et al., 2010).

Após a invasão, as tripomastigotas devem lançar mão de mecanismos de evasão do sistema imune para sobreviver ao ambiente altamente oxidado no interior dos macrófagos, com a finalidade de estabelecer a infecção. Para isso, o *T. cruzi* possui uma complexa rede de enzimas antioxidantes localizadas em diferentes compartimentos subcelulares que defendem o parasito contra um ambiente oxidado. Depois de se multiplicar e se transformar na forma tripomastigota sanguínea, os parasitos devem resistir a resposta imune humoral (De MORAES et al., 2015).

Mediante o reconhecimento entre o parasito e a célula do hospedeiro vertebrado, guiados pelo processo de sinalização celular, eles iniciam seu ciclo intracelular e são internalizados em um processo que envolve a formação de um vacúolo endocítico o vacúolo parasitóforo, seguindo vários ciclos de divisão celular que culminam com a disseminação do parasito para os tecidos (SOUZA,

CARVALHO e BARRIAS, 2010; TEIXEIRA et al., 2011; BARRIAS, CARVALHO e SOUZA, 2013).

Epting et al. (2010) e Moraes et al. (2015) relatam que o *T. cruzi* possui uma vasta diversidade de moléculas de superfície e secretadas que estão envolvidas direta ou indiretamente na adesão e invasão da célula hospedeira. Osorio et al. (2012) complementam que, as estruturas, estratégias ou moléculas produzidas por um agente patogênico no intuito de invadir e estabelecer relação de parasitismo no hospedeiro, provocando doença e evadindo das defesas do hospedeiro, define-se como fatores de virulência, que são listados na tabela 1.

Tabela 1 – Fatores de virulência expressados pelo *T. cruzi* durante sua interação com a célula hospedeira.

Fatores de Virulência envolvidos na resistência do <i>T. cruzi</i> ao estresse oxidativo	
	Referência(s)
Peroxidases (detoxificação de hidroperóxidos)	
Glutationa Peroxidase-I (TcGPXI)	Alvarez et al. (2004), Alvarez et al. (2011)
Glutationa Peroxidase-II (TcGPXII)	Alvarez et al. (2004), Alvarez et al. (2011)
Triparedoxina Peroxidase Citosólica (TcCPx)	Piacenza et al. (2008), Piacenza et al. (2009)
Triparedoxina Peroxidase Mitocondrial (TcMPx)	Piacenza et al. (2008), Piacenza et al. (2009)
Superóxido Dismutases	
Ferro superóxido dismutase (Fe-SOD)	Mateo et al. (2008)
Fatores de Virulência envolvidos na resistência do <i>T. cruzi</i> ao Sistema Imune da Célula Hospedeira e Evasão Imune	
	Referência(s)
Moléculas envolvidas na Resistência ao Sistema Complemento	
Fator de Aceleração de Decaimento do <i>T. cruzi</i> (T-DAF)	Norris et al. (1991), Tambourgi et al. (1993)
Proteína reguladora do complemento (CRP)	Norris et al. (1991), Norris et al. (1998), Beucher (2008)
Proteína trispanning inibidora do receptor de C2 (CRIT)	Cestari et al. (2008), Cestari et al. (2009), Blom et al. (2009)
Calreticulina (CRT)	Valck et al. (2010),

Prolina racemase (PR)	Ramirez et al. (2011) Chamond et al. (2005), Coutinho et al. (2009)
Tc52	Ouaisi et al. (1998), Ouaisi et al. (2002)
Evasão Imune mediada pela indução de microvesículas derivadas da célula hospedeira	Cestari et al. (2012)

Fatores de Virulência Envolvidos na Adesão e Invasão da Célula Hospedeira por Tripomastigotas	Referência(s)
gp82 e gp35/50	Atayde et al. (2004), Staquicini et al. (2010)
Mucinas	Bugliala et al. (2006), Alcaide et al. (2004)
Cruzipaína	Berasain et al. (2003), Alvarez et al. (2012)
Oligopeptidase B (OpB)	Burleigh et al. (1998), Coetzer et al. (2008)
gp85/Família Trans-sialidase (TS)	Magdesian et al. (2007), Tonelli et al. (2011)
Superfamília das TS	Lieke et al. (2011), Rubin e Schenkman (2012)
Calcineurina	Araya et al. (2009), Naderer et al. (2011)
Peptidil-prolil cis-trans Isomerase (TcMIP)	Moro et al. (1995)
Fosfolipase A1 (PLA1)	Belaunzaran et al. (2011)
Gp 63	Yao (2010)

Fatores de Virulência envolvidos no escape do <i>T. cruzi</i> do Fagolisossomo	Referência(s)
Tc-tox	Rubin-de-Celis et al. (2006)
LYT1	Zago et al. (2008)

Fatores de Virulência envolvidos na diferenciação ou proliferação do <i>T. cruzi</i>	Referência(s)
Proteasoma	de Diego et al. (2001)
Fosfatidilinositol Fosfolipase C (TcPI-PLC)	Vde et al. (2010)
Proteína Fosfatase 2A (TcPP2A)	Lauwaet et al. (2007), Madeira da Silva et al. (2010)
Calpaínas	Sangenito et al. (2009), Ennes-Vidal et al. (2010)

Assim, a invasão da célula hospedeira por tripomastigotas é um processo complexo, compreendendo diferentes etapas, envolvendo moléculas de adesão, eventos de sinalização e atividades proteolíticas.

No entanto, a patogenia da DC ainda permanece controversa. Diversas teorias tentam elucidar os mecanismos que provocam lesões teciduais e provocam intensas e severas disfunções, entre elas (1) persistência do parasito, (2) a proposta neurogênica e (3) a autoimunidade (TEIXEIRA, et al., 2011).

A teoria da persistência do parasito baseia-se na detecção precoce de ninhos de amastigotas nos tecidos musculares durante a fase aguda da infecção (TORRES, 1960). No entanto, a ausência de parasitismo nas lesões encontradas na fase crônica coloca em dúvida sua credibilidade, uma vez que aproximadamente 90% dos pacientes que morrem em decorrência da DC não apresentam parasitos nos tecidos (TORRES, et al., 2004; TEIXEIRA, et al., 2009).

A detecção de perdas significativas de neurônios em gânglios autonômicos e entéricos na ausência de *T. cruzi in situ*, é a base para a hipótese da liberação de uma neurotoxina do ninho do parasito escondido em alguma parte do corpo do hospedeiro (KOEBERLE, 1970). No entanto, não há relatos que demonstrem a estrutura da neurotoxina ou qualquer substância neurotóxica liberada pelo parasito (CILLARI, et al., 1995; TEIXEIRA, et al., 2011).

Já a teoria da autoimunidade é baseada na demonstração de uma interação citotóxica acelerada entre linfócitos T reativos ao *T. cruzi* com células alogênicas não parasitadas. Esses linfócitos aderem às miofibras e lisam as fibras musculares livres de parasitos. Além disso, são capazes de destruir neurônios dos plexos entéricos (TEIXEIRA, NASCIMENTO e STURM, 2006).

As respostas imunes contra antígenos próprios na DC humana e experimental foram demonstrados em vários estudos, entre os quais, anticorpos contra antígenos expressos em células cardíacas (MCCORNICK e ROWLAND 1989, CUNHA-NETO et al., 1995), células nervosas (RIBEIRO-dos-SANTOS et al., 1979, VAN VOORHIS e EISEN, 1989), entre outros, foram detectados durante a infecção pelo *T. cruzi*. No entanto, os autoanticorpos são comumente encontrados após a infecção com patógenos diferentes, sem qualquer implicação sobre uma patologia autoimune (ARGOV et al., 1989, DANIEL-RIBEIRO e ZANINI, 2000; SOARES, PONTES-de-CARVALHO e RIBEIRO-dos-SANTOS, 2001).

Dessa forma, Teixeira et al. (2011) concluem que a teoria da autoimunidade da DC continua sendo indefinida, uma vez que o mecanismo direto que reconhece o próprio como não-próprio e resulta na ativação de linfócitos inflamatórios efetores ainda é desconhecido.

1.3 Manifestações Clínicas da Doença de Chagas

A infecção que causa a DC apresenta duas fases bem definidas: a fase aguda e a fase crônica. A fase aguda, com duração de aproximadamente dois a três meses, com a ocorrência de sintomas não específicos, comumente encontrados em outras doenças que dificultam seu diagnóstico e caracterizada por uma parasitemia, febre, mal-estar, linfocitose e astenia. Poucos indivíduos desenvolvem síndromes clínicas severas nesta fase, porém cerca de 10% dos acometidos podem vir a óbito como resultado de severa miocardite ou meningoencefalite (RASSI-Jr, RASSI e MARIN-NETO, 2010; MONTGOMERY et al., 2014).

Segundo Montgomery et al. (2014), a fase aguda é diagnosticada pela identificação do parasito na circulação sanguínea com avaliação microscópica ou

hemocultura do sangue periférico. De acordo com Hofflin et al. (1987) e Grauert et al. (1993) a parasitemia desenvolve-se em uma fase indetectável microscopicamente (período pré-patente), outra detectável e crescente e uma terceira, detectável e decrescente.

Segundo os estudos de Correa Oliveira et al. (1999), as manifestações clínicas observadas na DC são em parte devido à resposta imune dirigida ao parasito. O sistema imune, portanto, estaria envolvido tanto na redução da carga parasitária quanto nas lesões teciduais verificadas na fase crônica da doença (CUNHA- NETO, 2014).

As manifestações da fase aguda da DC, geralmente, se resolvem espontaneamente em 90% dos indivíduos infectados, mesmo se a infecção não for tratada com drogas tripanocidas e aproximadamente 60% destes não manifestarão as formas clínicas cardíaca, neurológica, mista ou digestiva. Esses indivíduos possuem a forma indeterminada da DC que é caracterizada por ausência de sintomatologia clínica, sorologia positiva para *T. cruzi*, e eletrocardiograma e radiografias de tórax e abdome normais (DIAS, 1995; RASSI-Jr, RASSI e MARIN- NETO, 2010).

De acordo com Barrias, Carvalho e Souza (2013), 30 a 40% dos pacientes podem desenvolver uma forma crônica e sintomática da doença, que se desenvolve 10-20 anos após a infecção inicial, provocando lesões irreversíveis no coração, esôfago e intestino grosso com alteração na condução nervosa desses órgãos, caracterizando as formas clínicas: cardíaca, digestiva e neurológica. Durante a fase aguda da infecção experimental por *T. cruzi* observa-se uma curva de parasitemia, que por consequência leva a um intenso processo inflamatório com lesões secundárias em diversos tecidos do hospedeiro (COURA e BORGES-PEREIRA,

2010). Normalmente, o parasito não circula no sangue do hospedeiro durante a fase crônica (Da SILVEIRA, et al., 2007a; CAMPOS, et al., 2016). Por isso, assume-se que a maior parte das lesões teciduais observadas na DC ocorra na fase aguda da infecção (CAMPOS, et al., 2016).

A progressão direta da fase aguda para as formas clínicas da DC acomete uma pequena parcela dos pacientes (5 a 10%) (BRAZ, AMATO-NETO e OKAY, 2008). A reagudização da doença pode acontecer em indivíduos imunossuprimidos ou que fazem uso de medicamentos imunossupressores.

A morbimortalidade da DC ocorre principalmente na fase crônica, em decorrência de lesões teciduais que ocorrem ainda na fase aguda (RASSI e MARIN-NETO, 2010; MARTINS-MELO et al., 2012). Estudos epidemiológicos realizados em países da América Latina demonstram que 70% dos acometidos por DC são assintomáticos, e 30% podem desenvolver cardiopatia severa ou lesões digestivas ou distúrbios neurológicos. É importante ressaltar que a cada ano aproximadamente 2 a 3% dos indivíduos assintomáticos passam a manifestar alterações cardíacas, digestivas ou neurológicas (TEIXEIRA, NASCIMENTO e STURM, 2006; MAYA et al., 2010; ZINGALES, 2011; POVEDA, et al., 2014).

Segundo Verani et al. (2009) e Afonso, Ebell e Tarleton (2012), na fase crônica da DC o parasito pode ser encontrado esparsamente distribuído intracelularmente em tecidos por todo o corpo e raramente no sangue. O parasitismo não pode ser detectado por microscopia, mas apenas por mecanismos mais sensíveis como a PCR (Reação de cadeia da polimerase).

Como as manifestações gastrointestinais da DC provocam baixas taxas de mortalidade em comparação com as manifestações cardíacas, elas acabam recebendo pouca atenção por parte dos pesquisadores e até mesmo políticas

públicas de saúde, no entanto os pacientes que manifestam a forma digestiva da DC possuem altos índices de morbidade, o que resulta em uma qualidade de vida severamente prejudicada (PINAZO, et al., 2014).

A forma digestiva da DC é caracterizada por alterações na função motora, secretória e absortiva do trato gastrointestinal (RASSI, et al., 2010). Ela é encontrada quase que exclusivamente em países ao sul da bacia amazônica (Brasil, Chile, Argentina e Bolívia) e raramente em países da América Central e do Norte. Essa distribuição geográfica ocorre devido a diferenças nas cepas do parasito (RASSI, et al., 2010; RASSI-Jr, RASSI e MARIN-NETO, 2010).

As alterações nos órgãos do trato gastrointestinal que se manifestam durante a fase crônica da DC são atribuídas a lesões no plexo mientérico, resultando em movimentos peristálticos incoordenados, hipertrofia muscular e dilatação de órgãos como esôfago e intestinos (ADAD, et al., 2001; CAMPOS, et al., 2016). Em geral os sintomas digestivos são inespecíficos e diversos fatores, incluindo outras infecções comuns acabam gerando dificuldade no diagnóstico.

O megaesôfago e o megacólon são as maiores causas de morbidade na forma clínica digestiva da DC crônica (da SILVEIRA, et al., 2007ab; MATSUDA, MILLER e EVORA, 2009), sendo que para o desenvolvimento do megaesôfago é necessária uma redução de aproximadamente 85% do número de neurônios, e no megacólon, uma perda de pelo menos 50% do número de neurônios (KOEBERLE, 1970; TAFURI, MARIA e LOPES, 1970).

Ainda são escassos os estudos que visam a elucidar as alterações no sistema nervoso entérico após infecção por *T. cruzi*, bem como o papel das células inflamatórias no desenvolvimento das manifestações gastrointestinais. É possível que ocorra uma inflamação crônica ao redor dos gânglios entéricos nos indivíduos


infectados que desenvolvem os sintomas gastrointestinais (Da SILVEIRA, et al., 2007b). Acredita-se que a causa da morte neuronal durante a fase aguda da DC seja, em partes, provocada pela presença do parasito em altas concentrações nos tecidos (ANDRADE, 1983; Da SILVEIRA, et al., 2005), em contraste durante a fase crônica a carga parasitária é muito baixa nas lesões, assim a destruição dos neurônios mientéricos pode ser uma consequência da resposta imune que segue a infecção (VAGO, et al., 1996; Da SILVEIRA, et al., 2007a). Da Silveira, et al. (2007a) postulam que o processo inflamatório e a redução das células gliais encontradas em pacientes chagásicos pode perturbar o funcionamento do SNE, contribuindo para o desenvolvimento das manifestações gastrointestinais.

1.4 Neuropatia Entérica Chagásica

O trato gastrointestinal difere de todos os demais órgãos periféricos, pois é dotado de um extenso sistema nervoso intrínseco, denominado de sistema nervoso entérico (SNE), que pode controlar suas funções intestinais mesmo quando totalmente isolado do sistema nervoso central (Bayliss e Starling, 1899 APUD FURNESS, 2012).

O SNE é a maior e mais complexa divisão do sistema nervoso autônomo em vertebrados. Distribuído por todo o trato gastrointestinal (TGI), vesícula biliar e o pâncreas, é organizado como uma rede interconecta de neurônios e células da glia que são agrupados no interior de gânglios, localizados nos dois maiores plexos: o mientérico e o plexo submucoso, demonstrados na figura 3 (FURNESS, 2006).

Figura 3 – (A) Desenho esquemático dos plexos ganglionados do sistema nervoso entérico (Adaptado de Brehmer, 2006). (B) Organização do plexo mioentérico de humanos e mamíferos médios e grandes



Fonte: (Adaptado de Furness, 2006).

Os componentes do SNE formam um circuito integrado que desempenha diversas funções como o controle dos padrões de movimento do TGI, troca de fluidos por meio da superfície da mucosa, alterações no fluxo sanguíneo e interação com os sistemas imunológico e endócrino do intestino. Embora o TGI receba influência autonômica via sistema nervoso simpático e parassimpático, os circuitos neuronais intrínsecos do SNE são capazes de gerar atividade contrátil do intestino independente de intervenção do SNC (FURNESS, 2012; SASSELI, PACHNIS e BURNS, 2012).

Furness (2012), ressalta que o SNE, no entanto, não é autônomo, pois o controle neural da função gastrointestinal é um sistema integrado que envolve

interações entre reflexos entéricos locais, reflexos que passam por gânglios simpáticos e reflexos que passam pelo intestino e volta ao SNC.

Ele contém vários tipos diferentes de neurônios comparáveis em número ao da medula espinal (80-100 milhões) e uma série de neurotransmissores e neuromoduladores semelhantes aos encontrados no SNC. Com base nas propriedades eletrofisiológicas e histoquímicas podem ser classificados em subpopulações funcionalmente distintas, incluindo neurônios aferentes primários intrínsecos, interneurônios, neurônios motores, neurônios intestino-fugais, neurônios secretores e vasomotores (GIORGIO e CAMILLERI, 2004; BREHMER, 2006; FURNESS, 2006).

A maior parte dos neurônios mientéricos humanos são colinérgicos ou nitrérgicos (MURPHY, et al., 2007; JABARI, et al., 2014). Como em outras espécies os neurônios nitrérgicos humanos parecem ser interneurônios descendentes ou neurônios motores inibitórios (BREHMER, 2006). Em contraste, os neurônios mientéricos colinérgicos são neurônios motores excitatórios (FURNESS, 2006).

O VIP (peptídeo vasoativo intestinal) é um neuropeptídeo não-adrenérgico e não-colinérgico encontrado em neurônios secretomotores do intestino. Inervam diretamente o epitélio e regulam a concentração de íons e a secreção de fluidos (KEITA, et al., 2013). Em diferentes estudos VIP é demonstrado como regulador da resposta inflamatória (DELGADO e GANEA, 2001; CONLIN, et al., 2009). VIP é principalmente produzido por neurônios entéricos dos plexos mientérico e submucoso. Esse neuropeptídeo apresenta um potente efeito anti-inflamatório, afetando as respostas imunes inata e adaptativa (Di GIOVANGIULIO, et al., 2015).

Já a Substância P, um neuropeptídeo expresso em diversas regiões, incluindo o TGI é liberada principalmente por neurônios do plexo mientérico e submucoso,

bem como neurônios sensitivos intrínsecos e extrínsecos (GOODE, et al., 2000). Vários autores (STURIALE, et al., 1999; PELAYO, et al., 2014) sugerem um efeito pró-inflamatório para a SP na inflamação intestinal.

Os distúrbios de motilidade são comuns em pacientes com a forma digestiva da DC (da SILVEIRA, et al., 2007b; MATSUDA, MILLER e EVORA, 2009), os quais são decorrentes de lesões no plexo mientérico (MAIFRINO et al., 1999; ADAD et al., 2001; MEDEIROS, et al., 2010).

Estudos experimentais (MOREIRA, et al., 2011; MOREIRA et al., 2014; NOGUEIRA-PAIVA, et al., 2014) e em pacientes (da SILVEIRA, et al., 2007b; JABARI, et al., 2011; 2012; 2014) revelam morte de neurônios mientéricos durante a infecção chagásica. No entanto, Jabari et al. (2011) relatam que os neurônios nitrérgicos são mais resistentes aos fatores patológicos que levam à morte neuronal quando comparados com os neurônios colinérgicos.

A desnervação leva à perda de coordenação motora e alteração no funcionamento dos esfíncteres, e a musculatura lisa do segmento permanece em estado de contração (JABARI, et al., 2014), prejudicando o esvaziamento de material semissólido, provocando assim a dilatação, sendo este o mecanismo fisiopatológico subjacente ao megaesôfago e megacólon (RASSI, REZENDE e LUQUETTI, 2010).

No megacólon, os distúrbios da motilidade são relacionados com a dilatação do colo e a constipação. O reto e o colo sigmoide são os segmentos mais comprometidos (da SILVEIRA et al., 2007ab; JABARI et al., 2014). Assim, a dificuldade em defecar contribui para a dilatação do colo provocando dor e desconforto (TEIXEIRA et al., 2011).

O mecanismo patofisiológico que leva a lesão e morte neuronal observada na DC ainda é muito discutido no meio científico. Embora a maioria dos danos aos

neurônios do plexo mientérico e suas fibras nervosas ocorram durante a fase aguda da infecção devido à ação direta do parasito (JABARI, et al., 2014), grande perda neuronal ocorre lentamente ao longo da fase crônica da doença. A desnervação ocorre em graus variáveis, é irregular e provavelmente esteja relacionada com fatores próprios do hospedeiro e sua interação com o parasito (RASSI Jr, RASSI e REZENDE, 2012), reação de autoimunidade (DUTRA, et al., 2009), ou persistência do parasito no tecido do hospedeiro (da SILVEIRA, et al., 2005; CLAYTON, 2010).

No entanto, as lesões inflamatórias que acometem as fibras musculares e afetam os neurônios mientéricos (ADAD, et al., 2001; TEIXEIRA, NASCIMENTO e STURM, 2006; da SILVEIRA, et al., 2007a), estão fortemente associadas com a morte desses neurônios provocada pela lise mediada pelos linfócitos (TEIXEIRA, et al., 2011). Da Silveira et al. (2007b) complementam que o desenvolvimento do megacólon, após a infecção aguda por *T. cruzi* está associado com a invasão permanente dos gânglios entéricos por células T citotóxicas, levando a perda da inervação do músculo liso da parede do colo. Jabari et al. (2012) sugerem que o predomínio de fibras nervosas inibitórias intramusculares pode ser um fator importante no desenvolvimento do megacólon.

1.5 Tratamento Farmacológico da Doença de Chagas

O tratamento da DC constitui-se basicamente em controlar a replicação do parasito, particularmente nos casos agudos, congênitos, acidentes de laboratório, em casos crônicos de baixa idade e ocorrência de reinfecção e reagudização, além do tratamento sintomatológico durante o curso da infecção (MAYA, et al., 2010).

Existem no mercado dois fármacos para o tratamento da DC, o Benznidazol (Rochagan®, Roche Pharmaceutical, patente doada ao Ministério da Saúde, Brasil) e o Nifurtimox (Lampit®, Bayer Healthcare).

Nifurtimox e benznidazol atuam através da geração de radicais livres e/ou metabólitos eletrofílicos. O grupo nitro de ambos os fármacos é reduzido a um grupo amina pela ação das nitroredutases, formando intermediários de radicais livres e metabólitos eletrofílicos (MAYA, et al., 2007).

É provável que os metabólitos reduzidos do benznidazol estejam envolvidos nos efeitos tripanocidas por ligação colalente a macromoléculas (MAYA, et al., 2004). O benznidazol melhora a fagocitose e aumenta a morte de tripanossomas por intermédio do IFN- γ (ROMANHA, et al., 2002), promove ainda inibição da enzima NADH-fumarato redutase, que está presente no *T. cruzi* e catalisa a redução do fumarato gerando succinato. A atividade da enzima é importante na geração de energia do parasito (TURRENS, et al., 1996).

Diversos estudos relatam sobre os efeitos adverso com o uso do benznidazol, entre eles: dermatite alérgica, erupções cutâneas, edema generalizado, linfadenopatia, artralgia, prurido, distúrbios gastrointestinais (náusea, anorexia, vômito, diarreia, cólica intestinal), anorexia, perda de peso, cefaléia, neuropatia periférica (parestesia e hipoestesia astenia ou leve tremor das mãos). A depressão da medula óssea (púrpura trombocitopênica, agranulocitose e neutropenia) é um efeito adverso raro, sendo a neutropenia a manifestação mais frequente (STOPPANI, 1999; PONTES, et al., 2010; PINAZZO, et al., 2013).

O tratamento ainda não é efetivo para as duas fases clínicas da doença, sendo eficazes para o tratamento da doença quando administrados na fase aguda, alcançando índice de cura que varia de 30-70% (GONTIJO, GALVÃO e ELOI-

SANTOS, 1999). Entretanto, em virtude da DC na fase aguda se manifestar com sintomatologia pouco específica, grande parte dos indivíduos infectados não procuram o tratamento em decorrência da dificuldade de diagnóstico e tornam-se portadores crônicos da DC (RASSI, et al., 1999); momento em que os tratamentos são pouco eficazes (URBINA, 2010). No Brasil, o SUS (Sistema Único de Saúde) disponibiliza o medicamento benznidazol após prescrição médica, seja em casos agudos ou crônicos (FIOCRUZ, 2013).

De acordo com Abdalla et al. (2008), durante a fase aguda da DC, há um estado de imunossupressão evidenciado por uma baixa resposta humoral sobre antígenos parasitários específicos e não específicos, pela inibição da proliferação e apoptose de células T (FREIRE-DE-LIMA, et al., 2006), além de liberação de mediadores inflamatórios como a prostaglandina (PINGE-FILHO, et al., 1999), possibilitando que o *T. cruzi* possa evadir-se do sistema imune. Esse estado é mediado pela prostaglandina E2 (PGE2, ABDALLA, et al., 2008). As prostaglandinas são sintetizadas a partir do ácido araquidônico por meio da ação da enzima ciclo-oxigenase (COX). A PGE2 é um potente imunomodulador, com efeitos tanto estimuladores quanto inibidores (MAYA et al., 2010).

Experimentos realizados *in vitro* demonstraram que as PGE2 induzem a imunossupressão por interferir no processo de apresentação de antígeno, inibindo a expressão de molécula de MHC de classe II, provocando inibição da produção de IL-2 e redução da ativação de linfócitos T (HARRIS, et al., 2002; DURAND et al., 2009; GANZINELLI et al., 2009).

Abdalla et al., (2008) verificaram que níveis aumentados de PGE2 estavam relacionados a maior lesão tecidual no parênquima cardíaco de animais infectados com a cepa Y do *T. cruzi* e que o tratamento com drogas inibidoras seletivas para

COX-2 foi capaz de diminuir essas lesões e contribuir no aumento da síntese de óxido nítrico.

Freire-de-Lima et al. (2000) demonstraram que a prostaglandina E2 pode estar envolvida no processo de reprodução do parasito e que, portanto, inibidores de ciclooxigenases podem afetar este processo. Tatakihara et al. (2008) demonstraram que o uso de aspirina provocou aumento de ninhos amastigotas de *T. cruzi* no músculo cardíaco de camundongos C57BL/6, uma linhagem susceptível que apresenta progressiva imunossupressão que é correlacionada com o agravo da DC (PINGE-FILHO, 1999).

Os efeitos do tratamento com anti-inflamatórios não esteroidais (AINEs) inibidores das ciclooxigenases (COX) dentre eles a aspirina (ASA), ainda não estão totalmente esclarecidos na infecção chagásica. Os efeitos da ASA demonstram ser dose-dependente, uma vez que doses baixas (25 a 50mg/kg) exercem efeito protetor para o hospedeiro e doses acima de 50mg/kg aumentam a parasitemia e a taxa de mortalidade do hospedeiro (TATAKIHARA, et al., 2008; MUKHERJEE et al., 2011; MOLINA-BERRÍOS, et al., 2013a; MOLINA-BERRÍOS, et al., 2013b). Freire de Lima et al. (2000) encontraram redução da parasitemia, enquanto outros trabalhos mostram acréscimo da mortalidade e do parasitismo, especialmente no tecido cardíaco (TATAKIHARA et al., 2008). Não há relatos sobre efeitos do tratamento com ASA sobre o plexo mientérico do intestino durante a instalação da neuropatia entérica na infecção por *T. cruzi*.

O papel dos lipídios bioativos na DC ainda é muito inexplorado e complicado pelo fato de que o hospedeiro e o parasito são as principais fontes de síntese (MUKHERJEE et al., 2011). Estudos recentes destacam avanços no conhecimento dos mecanismos de resolução inflamatória. Nesses, sugerem que as lipoxinas são

promissoras ferramentas terapêuticas para o tratamento de doenças inflamatórias (MEDEIROS, et al., 2013) e que a inibição da COX-2 e a consequente redução na produção de PGE2 com um shift metabólico para derivados de lipoxinas tem a capacidade de diminuir a parasitemia e melhorar a mortalidade de camundongos infectados com *T. cruzi* (MOLINA-BERRÍOS, et al., 2013a).

No entanto, ainda são escassos os estudos que relacionam os efeitos do tratamento com ASA para reduzir os efeitos prejudiciais provenientes da infecção por *T. cruzi* na neuropatia entérica Chagásica.

2. OBJETIVO

2.1 OBJETIVO GERAL

Avaliar o efeito de baixas doses de aspirina (ASA) sobre neurônios mientéricos do cólon durante a fase aguda (20 mg/kg) ou crônica (50 mg/kg) durante a infecção murina por *T. cruzi*.

2.1.1 Objetivos Específicos

- Verificar se o tratamento com ASA na fase aguda ou na fase crônica da infecção provocada por *T. cruzi* é capaz de mudar o curso da infecção e proteger da desnervação a população neural mientérica;
- Avaliar se o tratamento com ASA interfere na plasticidade neuronal mientérica;
- Verificar se o protocolo experimental proposto provoca alteração na densidade celular e na morfometria das subpopulações neuronais produtoras de óxido nítrico, VIP e substância P, do plexo mientérico de camundongos infectados com *T. cruzi*.

The following paper was submitted as an ORIGINAL ARTICLE to the **Neurogastroenterology & Motility Journal** (Impact factor: 3.587)

Running Title: Aspirin treatment and infection with *T. cruzi*

MYENTERIC NEUROPROTECTIVE ROLE OF ASPIRIN IN ACUTE AND CHRONIC EXPERIMENTAL INFECTIONS WITH *Trypanosoma cruzi*

J. Y. Oda^{1,2}, M. O. Belém³, T. M. Carlos⁴, R. Gouveia⁴, N. M. Moreira⁵, C. L. Massocatto⁶, S. M. Araújo⁷, D. M. G. Sant'Ana⁶, N. C. Buttow⁶, P. Pinge-Filho², E. J. A. Araújo⁴

1. Department of Medicine, Federal University of Mato Grosso do Sul, Tres Lagoas, Mato Grosso do Sul, Brazil

2. Department of Pathological Science, State University of Londrina, Londrina, Parana, Brazil

3. Department of Physiology and Pharmacology, Federal University of Ceara, Fortaleza, Ceara, Brazil

4. Department of Histology, State University of Londrina, Londrina, Parana, Brazil

5. Center for Education, Letters and Health, State University of Western Parana, Foz do Iguaçu, Parana, Brazil

6. Department of Morphological Science, State University of Maringa, Maringa, Parana, Brazil

7. Department of Basic Health Science, State University of Maringa, Maringa, Parana, Brazil

Address for correspondence

Prof. Eduardo José de Almeida Araújo

Department of Histology, State University of Londrina

Rodovia Celso Garcia Cid PR 445, Km 380, 86051-990, Londrina, PR, Brazil

Tel: +55 (43) 3371 4327

ejaaraujo@gmail.com

ABSTRACT

Background Million individuals have Chagas disease and new cases are diagnosed every year in Latin America, North America, and Europe. Experimental and clinical studies have shown that myenteric neuron cell death during infection with *Trypanosoma cruzi* mainly occurs in the esophagus and colon, resulting in megaesophagus and megacolon, respectively. Evidences suggest that the cyclooxygenase enzyme (COX) is involved in the *T. cruzi* invasion process. The use of low-dose aspirin (ASA), a COX-1/COX-2 inhibitor, have been shown capable to reduce infection with *T. cruzi*. Therefore, in this study, we evaluated the effects of treatment with low-dose ASA on myenteric colonic neurons during murine infection with *T. cruzi*. **Methods** Swiss mice were assigned into groups treated with either phosphate-buffered saline or low doses of ASA during the acute phase (20 mg/kg) and chronic phase (50 mg/kg) of infection with the Y strain of *T. cruzi*. Seventy-five days after infection, colon samples were collected to quantify inflammatory foci in histological sections and also general (myosin-V⁺), nitrenergic, and VIPergic myenteric neurons in whole mounts. Gastrointestinal transit was also measured. **Key results** ASA treatment during the acute phase of infection reduced parasitemia ($p < 0.05$). ASA treatment reduced the intensity of inflammatory foci in the colon, protected myenteric neurons from cell death and plastic changes, and recovered the gastrointestinal transit of mice infected with *T. cruzi* ($p < 0.05$). **Conclusion & Inferences** Thus, treatment with low-dose ASA can reduce the morphofunctional damage of colonic myenteric neurons caused by murine *T. cruzi* infection.

Keywords: American trypanosomiasis, Chagas disease, enteric denervation, enteric nervous system, nonsteroidal anti-inflammatory drugs.

KEY POINTS

- 1) Colonic motility disorders occur because of myenteric neuron death, which is caused by inflammatory processes in the digestive tract.
- 2) During the acute and chronic phases of experimental infection with *Trypanosoma cruzi*, administration of low doses of ASA reduced the intensity of colonic inflammatory foci, protected myenteric neurons against cell death, and recovered the gastrointestinal transit in mice.
- 3) The use of low doses of ASA may represent a therapeutic alternative for Chagas disease and should be evaluated in combined treatment with benznidazole.

INTRODUCTION

Approximately 7–8 million individuals have Chagas disease (American trypanosomiasis) and 50,000 new cases are diagnosed every year in Latin America, North America, and Europe^{1,2}. It is estimated that more than 90 million individuals are currently at risk of infection with the Chagas disease etiologic agent (*Trypanosoma cruzi*)^{2,3}. Furthermore, slightly invasive or non-invasive strains of *Trypanosoma cruzi* (CL-14 and G strains) are capable of infecting mice with gastric lesions⁴, indicating that the number of oral infection cases has potential to increase.

The Chagas disease-associated morbidity and mortality occur mainly during the chronic phase, as a result of tissue damage during the acute phase^{5,6}. Although many infected individuals remain asymptomatic during their lives^{5,7}, 30–40% develop cardiac⁸, neurologic^{1,5}, digestive^{3,8,9}, or mixed complications.

Motility disorders commonly occur in patients with digestive form of Chagas disease^{10,11} as a result of myenteric plexus lesions. Experimental^{12,13,14} and clinical studies^{10,15,16,17} have shown that myenteric neuron cell death during infection with *T. cruzi* mainly occurs in the esophagus and colon, resulting in megaesophagus and megacolon, respectively^{10,17}. However, there is evidence of selective and partial survival of nitrergic and VIPergic neurons^{15,16}. There is no agreement regarding the

cause of myenteric neuron death; however, the most accepted hypothesis is that it is associated with an inflammatory process induced by the presence of the parasite^{3,10,18,19}.

Evidence suggests that the cyclooxygenase enzyme is involved in the *T. cruzi* invasion process²⁰. Thus, the use of aspirin (ASA) and celecoxib, respective COX-1/COX-2 and COX-2 inhibitors, can inhibit infection with *T. cruzi*^{20,21}. The effects of ASA have been shown to be dose-dependent, as low doses (20–50 mg/kg) have a protective effect and doses above 50 mg/kg increase host parasitemia and mortality rates in mice^{22,23,24,25}.

The objective of this study was to evaluate the effects of low doses of ASA on colonic myenteric neurons during the acute phase (20 mg/kg) or chronic phase (50 mg/kg) of murine infection with *T. cruzi*.

MATERIALS AND METHODS

All performed procedures were approved by the Animal Ethics Committee of the State University of Londrina (Reference number: 156/2012).

Experimental groups

Sixty-day-old male Swiss mice (*Mus musculus*) weighing 25–30 g were sourced from the animal house at State University of Londrina (Brazil). Mice were kept in polypropylene boxes in groups of five individuals under standardized conditions: 21–23°C and 12-h light/dark cycle. Rodent chow (Nuvilab CR1 from Nutrient Nuvil Ltda.[®], Curitiba, Brazil) and water were provided *ad libitum*.

Mice were randomly assigned into six groups (Fig. 1A). Two groups were treated 0.1 M phosphate-buffered saline (PBS, pH 7.4); the remaining four groups

were treated with ASA (A2093 from Sigma-Aldrich, St. Louis, MO, USA). One PBS-treated-group and two ASA-treated-groups were infected with 1,300 blood trypomastigotes of *T. cruzi* (Y strain) via i.p.. The trypomastigotes were sourced from the Parasitology Laboratory of the Department of Basic Health Science at State University of Maringá (Brazil). To induce the chronic phase of *T. cruzi* infection, 100 mg/kg doses of benznidazole (Rochagan® from Roche Pharmaceuticals, Mannheim, Germany, patent donated to the Brazilian Ministry of Health) were administered by gavage on days 11, 13, 15, 25, 29, and 48 post infection¹² (dpi). ASA treatment was performed during the acute phase (Fig. 1B) or chronic phase (Fig. 1C) of infection with *T. cruzi*. The doses and duration of the ASA treatment in this experiment were defined for an exploratory study.

Course of experimental infection

Host parasitemia was evaluated using Brener's Method (1962)²⁶, counting the parasite number in 5 µL of blood extracted from the mice tail each day on days 4–15 dpi. The parasitemia curve was plotted using the average count of parasites in the infected mice.

Euthanasia and colon collection

All mice were euthanized using an euthanasia chamber with halothane vapor saturation (Tanohalo®) at 135 days of age (75 dpi). Colon extraction was performed and its length and width were measured in order to calculate total area.

Inflammatory infiltrate analysis

One centimeter distal segment of each colon was used to histological processing in order to obtain four semi-serial histological sections stained with hematoxylin-eosin. All sections were 5- μm thick and 20 μm away from each other.

For inflammatory foci evaluation, 10 microscopic field magnified by 400X were analyzed in each section (1.9 mm^2 total area). Foci were classified as absent (0–9 inflammatory cells), discrete (10–24 inflammatory cells), moderate (25–50 inflammatory cells), and intense (50+ inflammatory cells), as suggested by Michailowsky et. al.²⁷. Final results were obtained by summing the number of inflammatory cells observed in each histological section.

Myenteric plexus evaluation

Immunofluorescence

Colons were washed with 0.1 M PBS (pH 7.4) and fixed using Zamboni's fixative solution for 18 h at 4°C. After washing with different concentrations of ethanol, the colons were stored in 0.1 M PBS, pH 7.4, containing 0.08% sodium azide at 4°C for microdissection using a stereomicroscope. Whole mounts containing the external muscular layer and myenteric plexus were processed according to standard immunofluorescence technique using the antibodies shown in Table 1.

Quantitative analysis

The total number of myenteric neurons immunoreactive (IR) to myosin-V (a general marker), neuronal nitric oxide synthase (nNOS), and vasoactive intestinal polypeptide (VIP) was counted using 35 images captured with a high-definition camera (AxioCam, Carl Zeiss, Jena, Germany) coupled to a fluorescence

microscope (Axioskop Plus light microscope, Carl Zeiss) using a 20X objective lens. The difference between the number of myosin-V-IR neurons and nNOS-IR neurons was used as the estimated number of cholinergic neurons as suggested by Philips et al²⁸. The counting result was extrapolated to 1 cm².

Morphometric analysis

Three hundred myenteric cell body area (μm^2) immunoreactive to myosin-V, nNOS, and VIP of each mouse was measured using Image Pro-Plus 4.5v software (Media Cybernetics, Rockville, MD, USA). Furthermore, 700 VIPergic myenteric varicosities and 700 varicosities containing substance P (SP) of each mouse were measured using the same software.

Bright field analysis

Bright field intensity was evaluated in 60 images captured with a high-definition camera (AxioCam, Carl Zeiss) using a 40X objective lens. The image capture settings (exposure, gain, and offset) were standardized during the experiment in order to avoid external influences on image brightness. The bright field intensity was analyzed using ImageJ 1.48v software (NIH, Bethesda, MD, USA). For this purpose, the area containing the myenteric ganglion was selected. Areas of different images and the bright field intensity of each mouse were summed. The values found in each mouse were extrapolated to 1 cm².

Gastrointestinal transit time evaluation

The gastrointestinal transit time was evaluated by administering a non-absorbable marker (3% carmine red and 0.5% ethylcellulose) by gavage²⁹. The mice

were assigned into individual boxes containing food and water. The time required for elimination of the first evacuated red pellet was considered as the gastrointestinal transit time.

Statistical analysis

All data were expressed as the mean \pm standard error of the mean. Data were analyzed to determine the distribution using the Shapiro-Wilk test. The Mann-Whitney test was performed to analyze parasitological parameters. For the other parameters, significant statistical differences were identified using the one-way ANOVA test, followed by Tukey's test. For this purpose, the GraphPad Prism6 software (GraphPad Software Inc. San Diego, USA) was used. The significance level was set to 5%.

RESULTS

Effects of ASA in the course of infection by *T. cruzi*

The parasitemia curve of the three groups infected with *T. cruzi* (PBS, ASA_{Early} and ASA_{Delayed}) showed the characteristic profile of the Y strain. ASA treatment during the acute phase (ASA_{Early}) reduced the peak parasitemia by 46% by day 8 ($p < 0.01$), 65% by day 9 ($p < 0.01$), and 75% by day 11 ($p < 0.01$) after infection, thus contributing to the reduction in total parasitemia ($p < 0.01$) (Fig. 1D).

ASA treatment reduces the number of inflammatory foci

Even after 75 dpi with *T. cruzi*, the infected mice treated with PBS showed intense ($p < 0.01$) inflammatory foci in the colonic wall. ASA treatment during the acute and chronic phases of the infection was capable to reduce the number of inflammatory foci in the colonic wall ($p < 0.01$; Fig. 2).

Neuroprotective effect of ASA treatment during the infection with *T. cruzi*

PBS-treated-mice infected with *T. cruzi* presented intense myenteric neuron loss in the general population (60.7%; Fig. 3A–3D) and nitrergic (49.0%; Fig. 4A–4D), VIP (38.0%; Fig. 5A–5D), and cholinergic (67.0%; Fig. 6A) subpopulations. Neuronal death was dramatically reduced by ASA treatment in both the acute and chronic phases of infection ($p < 0.01$; Fig. 3A, 3E–3F, 4A, 4E–4F, 5A, 5E–5F). However, more intense death of the cholinergic population was observed (Fig. 6A). As there were no modifications in the colonic area ($p > 0.05$), the neuronal population density showed myenteric denervation in groups infected with *T. cruzi*. The high cholinergic neuronal death rate in the infected mice from the PBS group caused a significant delay in gastrointestinal transit ($p < 0.01$; Fig. 6B). ASA treatment contributed to gastrointestinal transit of the infected mice had no difference compared with the uninfected mice ($p > 0.01$; Fig. 6B). Notably, ASA treatment of uninfected mice led to a discrete (15.0%) neuronal death (Fig. 3A), mainly for the cholinergic population (Fig. 6A).

The cell body of the remaining neurons of the PBS-treated-mice infected with *T. cruzi* became hypertrophic. ASA treatment during the acute phase of infection contributed most significantly to maintaining the cell body area of the remaining myenteric neurons ($p < 0.05$; Fig. 3B, 4B, and 5B). Additionally, ASA treatment of uninfected mice led to cell body atrophy of myenteric neurons ($p < 0.05$; Fig. 3B and 5B). PBS-treated-mice infected with *T. cruzi* showed atrophied VIPergic myenteric varicosities and hypertrophied myenteric varicosities containing substance P ($p < 0.05$; Fig. 6C and 6D). Furthermore, myenteric nerve fibers showed higher bright field intensity when marked for SP in PBS-treated-mice infected with *T. cruzi* ($p < 0.05$;

Fig. 6E). None of the ASA treatments contributed to restoring the balance of VIP and substance P ($p > 0.05$; Fig. 6C–6E).

DISCUSSION

This is the first study to investigate the effects of ASA treatment for colonic neuropathy caused by *T. cruzi*. Low-dose ASA treatments reduced the lesions resulting from murine infection with *T. cruzi*. It was observed lowered parasitemia, decreased inflammatory foci in the colonic wall, protection of myenteric neurons, and reestablishment of gastrointestinal transit.

The parasitemia curve observed during the acute phase of the experimental infection with *T. cruzi* leads to an intense inflammatory process with secondary lesions in several tissues³⁰. Typically, the parasite does not circulate in the host's blood during the chronic phase^{10,19}. Therefore, it is assumed that most tissue lesions observed in Chagas disease occur during the acute phase of infection¹⁹. Lower parasitemia was observed in BALB/c mice treated with 5–50 mg/kg of ASA during the acute phase of infection with *T. cruzi*²⁴. However, Mukherjee et al.²³ reported an increase in parasitemia and the mortality of C57BL/6 and CH3/HeJ mice treated with 20 and 50 mg/kg of ASA during the acute phase of infection with *T. cruzi*. The results of experimental studies evaluating the treatment with nonsteroidal anti-inflammatories during the infection with *T. cruzi* are controversial. In general, these results vary according to the administered drug^{20,21,31} and its doses^{23,24,25}, as well as also according to the species and strains of the host³². Furthermore, the *T. cruzi* strain³³ may interfere with the results.

Low-dose ASA treatments for *T. cruzi*-infected mice have shown a protective effect against lesions observed during the course of infection³⁴. This effect may be

related to NF- κ B translocation to the nucleus^{35,36,37}, alternative production of 15-epi-lipoxin-A₄³⁶, and increase in anti-inflammatory cytokines^{36,38}. As a result, inflammatory mediators are reduced, which can explain the reduction of inflammatory foci found in the colonic wall of ASA_{Early}- and ASA_{Delayed}-infected mice groups. These findings were also observed in the heart of BALB/c mice treated with 25–50 mg/kg of ASA²⁴. This inflammatory process control can contribute to a better survival rate of mice infected by *T. cruzi*¹⁸. Therefore, the use of low doses of ASA may represent a therapeutic alternative against the evolution of Chagas disease²⁰ and should be evaluated in combined treatment with benznidazole, the only trypanocidal drug available in Brazil for humans³⁹.

Several studies have detected intense denervation in the myenteric plexus during infection with *T. cruzi*^{10,12,40,41,42}, which was also observed in the infected mice colon samples used in this study. However, in a parallel study using the same mice, myenteric denervation was not found in nitrergic neurons of the esophagus³⁴. Myenteric neuronal losses are consistent with clinical findings of the digestive form of Chagas disease^{10,17,42}. It has been suggested that this loss is related to the inflammatory process caused by *T. cruzi*^{19,41}, and thus is related to parasitemia³. ASA_{Early} and ASA_{Delayed} treatment protected the colonic myenteric neurons. Because the parasitemia curve did not change for mice treated with ASA during the chronic phase of infection, the mechanisms involved in preserving myenteric neurons with low-dose treatment with ASA may be related to reducing the inflammatory process during infection with *T. cruzi* rather to control the parasitemia.

Our results revealed higher denervation of cholinergic myenteric neurons in PBS-treated-mice infected with *T. cruzi*. These results differ from those of Da Silveira et al.⁴² in chagasic humans, which showed a higher denervation of nitrergic and

VIPergic myenteric neurons. However, Jabari et al.^{15,16,17} observed a selective survival of nitrergic and VIPergic myenteric neurons in chagasic humans, suggesting that these types of neurons are more resistant to neuronal death provoked by Chagas disease. Nitrergic myenteric neuronal death was not observed in the esophagus of the PBS-treated-mice infected with *T. cruzi*³⁴. Some authors have suggested that the survival imbalance between excitatory and inhibitory motor neurons is strongly associated to the chagasic megacolon pathology^{10,43}.

Regarding the death and survival of neurons, we observed a discrete reduction in the number of neurons in uninfected mice treated with ASA. Additional studies are required to investigate whether the use of low-doses of ASA can cause myenteric neuronal death.

Studies have indicated that the relationship between reduction in myenteric neurons and modifications of contractility can determine digestive symptoms of the Chagas disease^{10,41,44}. Campos et al.¹⁹ suggested that myenteric denervation and the formation of fibrotic areas, resulting from intense inflammatory processes, may modify the smooth muscle architecture and promote modifications in the intermuscular nerve fibers, thus resulting in symptoms such as constipation. In this study, a higher cholinergic myenteric neuron loss was observed compared to that for nitrergic myenteric neurons in the PBS-treated-mice infected with *T. cruzi*, resulting in delayed gastrointestinal transit. ASA_{Early} and ASA_{Delayed} treatment partially preserved myenteric neurons from cell death and thus was efficient for maintaining the gastrointestinal transit.

Regarding the myenteric neuronal morphometric, we observed that the infection with *T. cruzi* led to hypertrophy of the remaining neurons in the PBS-treated-mice. This result was similar to those of previous studies, which analyzed the

myenteric plexus of humans⁴¹ and mice^{12,45} infected with *T. cruzi*. However, atrophied nitrergic myenteric neurons were found in the esophagus of the PBS-treated-mice³⁴. The increase in the neuronal cell body size may be related to a morphological adaptation (neuronal plasticity) as a compensatory mechanism related to higher physiological activity and resulting in greater neurotransmitter release, such as nitric oxide (NO) and the VIP. An increased level of NO promotes over relaxation of the muscle layer and peristaltic disorders; both of these characteristics are common in Chagas disease^{15,46}. VIP has been shown to have neuroprotective^{47,48,49} and neuroeffector⁵⁰ roles in Chagas disease. Jabari et al.¹⁶ suggested that VIP can protect neurons from death, despite the colonic motility being irreversibly disrupted. Only ASA_{Early} treatment was able to control the hypertrophy of the all evaluated myenteric neuronal populations in infected mice. The ASA_{Delayed} treatment was not able to control the hypertrophy of the nitrergic myenteric neuronal population in infected mice. This indicates that although inflammatory process control was established by the ASA_{Delayed} treatment, it was unable to restore the nitrergic myenteric neuronal area. ASA treatment minimized atrophy of the nitrergic myenteric neurons in the esophagus of PBS-treated-mice infected with *T. cruzi*³⁴.

Dutra et al.⁵¹ reported that increased VIP levels and decreased SP levels induce regulatory cytokines, resulting in the indeterminate form of Chagas disease. However, a microenvironment with decreased VIP levels and increased SP levels promotes an increasing of pro-inflammatory cytokines, resulting in the various clinical forms of Chagas disease. Accordingly, larger varicosities containing SP and smaller varicosities containing VIP were found in PBS-treated-mice infected with *T. cruzi*. Furthermore, SP-producing nerve fibers were brighter in these mice, indicating a larger amount of this neuropeptide. This suggests that PBS-treated-mice infected

with *T. cruzi* showed an imbalance contributing to the development of clinical forms of Chagas disease. The VIPergic and SP varicosities behaved in opposite manners based on the results for the ASA_{Early} and ASA_{Delayed} treatment. However, ASA treatment did not show a significant difference from PBS-treated-mice infected with *T. cruzi*. On the other hand, both ASA_{Early} and ASA_{Delayed} treatments reduced the number of inflammatory foci in the colonic wall. Considering the role of VIP and SP in inflammatory process^{49,51}, the strong influence of these two neuropeptides over colonic motility⁴³ and their contribution to the physiopathology of Chagas disease^{10,16,17,47,48,49}, we suggest that ASA treatment positively influenced the balance of these two neuropeptides. This benefic effect occurred regardless of whether ASA treatment was performed during the acute or chronic phase, as treatment in both phases appeared to be effective for reducing inflammatory foci and recovering the gastrointestinal transit.

We conclude that only the ASA_{Early} treatment was capable of reducing parasitemia. Both ASA_{Early} and ASA_{Delayed} treatments were capable of reducing the intensity of inflammatory foci in the colonic wall, protecting myenteric neurons against cell death and plastic changes, and recovering the gastrointestinal transit in mice infected with the Y strain of *T. cruzi*. Therefore, low-dose ASA treatment reduces myenteric neuron loss in the colon of mice infected with *T. cruzi*.

AKNOWLEDGEMENTS, FUNDING, AND DISCLOSURES

This paper is part of the JYO's PhD thesis. We thank the Araucaria Foundation for Scientific and Technological Development (Brazil) for the grant given through the agreement number 319/2012, and the Federal University of Mato Grosso do Sul (Brazil) for providing JYO's training license.

AUTHORS CONTRIBUTIONS

JYO acquisition of data, statistical analysis, interpretation of data and drafting of the manuscript; MOB, TMC, RG, NMM & CLM acquisition of data and technical support; SMA *Trypanosoma cruzi* providing and critical revision of the manuscript for important intellectual content; DMGS study design and critical revision of the manuscript for important intellectual content; NCB antibody against mision-V providing and critical revision of the manuscript for important intellectual content; PPF study design, critical revision of the manuscript for important intellectual content and study supervision (second supervisor); EJAA Senior author, study design, obtained funding from Araucária Foundation for Scientific and Technological Development (Brazil), critical revision of the manuscript for important intellectual content, study supervision (first supervisor); All authors approved of the final version submitted.

REFERENCES

1. Coura, JR, Dias, JCP. Epidemiology, control and surveillance of Chagas disease – 100 years after its discovery. *Mem Inst Oswaldo Cruz* 2009;104(Suppl 1):31-40.
2. WHO. World Health Organization. Chagas disease (American trypanosomiasis) Available in: <http://www.who.int/mediacentre/factsheets/fs340/en/> . Accessed 02-08-2014.
3. Vazquez, BP, Vazquez, TP, Miguel, CB, Rodrigues, WF, Mendes, MT, Oliveira, CJF, Chica, JEL. Inflammatory responses and intestinal injury development during acute *Trypanosoma cruzi* infection are associated with the parasite load. *Parasites & Vectors* 2015; 8:206.
4. Cossentini, LA, Da Silva, RV, Yamada-Ogatta, SF, Yamauchi, LM, Araújo, EJA, Pinge-Filho, P. Aspirin treatment exacerbates oral infections by *Trypanosoma cruzi*. *Experimental Parasitology* 2016;164:64-70.
5. Rassi Jr, A, Rassi, A, Marin-Neto, JA. Chagas disease. *Lancet* 2010;375:1388-402.
6. Martins-Melo FR, Ramos AN, Alencar CH, Heukelbach J. Mortality related to Chagas disease and HIV/AIDS coinfection in Brazil. *J Tropical Med* 2012;2012:1–4.

7. Maya, JD, Orellana, M, Ferreira, J, Kemmerling, U, Lopez-Muños, R, Morello, A. Chagas disease: presente status of pathogenic mechanisms and chemotherapy. *Biol Res* 2010;43:323-331.
8. Zingales, B, Miles, MA, Moraes, CB, Luquetti, A, Guhl, F, Schijman, A, Ribeiro, I. Drug discovery for Chagas disease should consider *Trypanosoma cruzi* strain diversity. *Mem Inst Oswaldo Cruz* 2014;109(6):828-833.
9. Poveda C, Fresno M, Girones N, Martins-Filho OA, Ramirez JD, et al. Cytokine Profiling in Chagas Disease: Towards Understanding the Association with Infecting *Trypanosoma cruzi* Discrete Typing Units (A BENEFIT TRIAL Sub-Study). *PLoS ONE* 2014;9(3): e91154.
10. Da Silveira, ABM, Lemos, EM, Adad, SJ, Correa-Oliveira, R, Furness, JB, Reis, DD. Megacolon in Chagas disease: a study of inflammatory cells, enteric nerves, and glial cells. *Human Pathology* 2007;38:1256-1264.
11. Matsuda, NM, Miller, MS, SM, Evora, PRB. The chronic gastrointestinal manifestations of Chagas disease. *Clinics* 2009;64(12):1219-24.
12. Moreira, NM, Sant'Ana, DMG, Araújo, EJA, Toledo, MJO, Gomes, ML, Araújo, SM. Neuronal changes caused by *Trypanosoma cruzi*: an experimental model. *Anais da Academia Brasileira de Ciências* 2011;83(2):545-555.
13. Moreira, NM, Zanoni, JN, Dalálio, MMO, Araújo, EJA, Braga, CF, Araújo, SM. Physical exercise protects myenteric neurons and reduces parasitemia in *Trypanosoma cruzi* infection. *Experimental Parasitology* 2014;141:68-74.
14. Nogueira-Paiva, NC, Fonseca, KS, Vieira, PMA, Diniz, LF, Caldas, IS, et al. Myenteric plexus is differentially affected by infection with distinct *Trypanosoma cruzi* strains in Beagle dogs. *Mem Inst Oswaldo Cruz* 2014;109:51-60.
15. Jabari, S, Da Silveira, ABM, Oliveira, EC, Neto, SG, Quint, K, Neuhuber, W, Brehmer, A. Partial, selective survival of nitergic neurons in chagasic megacolon. *Histochem Cell Biol* 2011;135:47-57.

16. Jabari, S, Da Silveira, ABM, Oliveira, EC, Neto, SG, Quint, K, Neuhuber, W, Brehmer, A. Selective survival of calretinin- and vasoactive-intestinalpeptide-containing nerve elements in human chagasic submucosa and mucosa. *Cell Tissues Res* 2012; 349:473-481.
17. Jabari, S, Oliveira, EC, Brehmer, A, Da Silveira, ABM. Chagasic megacolon: enteric neurons and related structures. *Histochem Cell Biol* 2014;142:235-244.
18. Pavanelli, WR, Gutierrez, FRS, Mariano, FS, Prado, CM, Ferreira, BR, et al. 5-Lipoxygenase is a key determinant of acute myocardial inflammation and mortality during *Trypanosoma cruzi* infection. *Microbes and Infection* 2010;12:587-597.
19. Campos CF, Cangussú SD, Duz ALC, Cartelle CT, Noviello MdL, Veloso VM, et al. Enteric Neuronal Damage, Intramuscular Denervation and Smooth Muscle Phenotype Changes as Mechanisms of Chagasic Megacolon: Evidence from a Long-Term Murine Model of *Trypanosoma cruzi* Infection. *Plos ONE* 2016;11(4): e0153038. doi:10.1371/journal.pone.0153038.
20. Malvezi, AD, Panis, C, Da Silva, RV, Freitas, RC, Lovo-Martins, MI, Tatakihara, VL, et al. Inhibition of Cyclooxygenase-1 and Cyclooxygenase-2 Impairs *Trypanosoma cruzi* entry into cardiac cells and promotes differential modulation of the inflammatory response. *Antimicrobial Agents and Chemotherapy* 2014;10:6157-6164.
21. Malvezi, AD, Da Silva, RV, Panis, C, Yamauchi, LM, Lovo-Martins, MI, Zanluqui, NG, et al. Aspirin modulates innate inflammatory response and inhibits the entry of *Trypanosoma cruzi* in mouse peritoneal macrophages. *Mediators of Inflammation* 2014; 580919. doi: 10.1155/2014/580919.
22. Tatakihara VL, Cecchini R, Borges CL, Malvezi AD, Graca-de Souza VK, et al. Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine *Trypanosoma cruzi* infection. *FEMS Immunol Med Microbiol* 2008;52:47-58.
23. Mukherjee, S, Machado, FS, Huang, H, Oz, HS, Jelicks, LO, Prado, CM, et al. Aspirin treatment of mice infected with *Trypanosoma cruzi* and implications for the pathogenesis of Chagas disease. *Plos ONE* 2011;6(2):e16959.

24. Molina-Bérríos, A, Campos-Estrada, C, Henriquez, N, Faúndez, M, Torres, G, et al. Protective role of acetylsalicylic acid in experimental *Trypanosoma cruzi* infection: evidence of 15-epi-Lipoxin A4-Mediated effect. *PLoS Negl Trop Dis* 2013;7(4):e2173.
25. Molina-Bérríos, A, Campos-Estrada, C, Lapier, M, Duaso, J, Kemmerling, U, et al. Protection of vascular endothelium by aspirin in a murine model of chronic Chagas disease. *Parasitol Res* 2013;112:2731-2739.
26. Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with *Trypanosoma cruzi*. *Rev Inst Med Trop* 1962; 4: 389–96.
27. Michailowsky, V, Silva, NM, Rocha, CD, Vieira, LQ, Lannes-Vieira, J, Gazzinelli, RT. Pivotal role of interleukin-12 and interferon gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during *Trypanosoma cruzi* infection. *American Journal of Pathology* 2001;109(5):1723-1733.
28. Phillips, RJ, Kieffer, EJ, Powley, TL. Aging of the myenteric plexus: neuronal loss is specific to cholinergic neurons. *Auton Neurosci* 2003;106(2):69-83.
29. Calcina, F, Barocelli, E, Bertoni, S, Furukawa, O, et al. Effect of *N*-Methyl-D-Aspartate receptor blockade on neuronal plasticity and gastrointestinal transit delay induced by ischemia/reperfusion in rats. *Neuroscience* 2005;134:39-49.
30. Coura, JR, Borges-Pereira, J. Chagas disease: 100 years after its discovery. A systemic review. *Acta Tropica* 2010;115:5-13.
31. Lopez-Muños, R, Faúndez, M, Klein, S, Escanilla, S, et al. *Trypanosoma cruzi*: in vitro effect of aspirin with nifurtimox and benznidazole. *Experimental Parasitology* 2010;124:167-171.
32. Roggero, E, Perez, A, Tamae-Kakazu, M, Piazzon, I, Nepomnaschy I, et al. Differential susceptibility to acute *Trypanosoma cruzi* infection in BALB/c and C57BL/6 mice is not associated with a distinct parasite load but cytokine abnormalities. *Clin Exp Immunol* 2002;128:421-428.

33. Caetano, LC, Prado Jr, JC, Toldo, MPA, Abrahão, AAC. *Trypanosoma cruzi*: do different sylvatic strains trigger distinct immune responses? *Experimental Parasitology* 2010;124:219-224.
34. Massocatto CL, Moreira NM, Muniz E, Pinge-Filho P, Rossi RM, Araújo EJ, Sant'Ana DM. Aspirin prevents atrophy of esophageal nitrergic myenteric neurons in a mouse model of chronic Chagas disease. *Dis Esophagus* 2016; doi: 10.1111/dote.12449.
35. Moro, MA, De Alba, J, Cárdenas, A, De Cristóbal, J, Leza, JC, et al. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain slices. *Neuropharmacology* 2000;39(7):1309-18.
36. Medeiros, R, Kitazawa, M, Passos, GF, Baglietto-Vargas, D, Cheng, D. et al. Aspirin-Triggered Lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. *The American Journal of Pathology* 2013;182(5).
37. Asanuma, M, Nishibayashi-Asanuma, S, Miyazaki, I, Kohno, M, Ogawa, N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. *Journal of Neurochemistry* 2001; 76:1895-1904.
38. Morris, T, Stables, M, Hobbs, A, Souza, P, Colville-Nash, P, Warner, T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. *The Journal of Immunology* 2009;183(3):2089-2096.
39. Caldas IS, Talvani A, Caldas S, Carneiro CM, de Lana M, da Matta Guedes PM, et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. *Parasitol Res* 2008;103(2):413-21.
40. Maifrino, LBM, Liberti, EA, Watanabe, IS, Souza, RR. Morphometry and acetylcholinesterase activity of the myenteric neurons of the mouse colon in the chronic phase of experimental *Trypanosoma cruzi* infection. *Am J Trop Med Hyg* 1999;60(5):721-725.

41. Adad SJ, Cançado CG, Etchebehere RM, Teixeira VP, Gomes UA, Chapadeiro E, et al. Neuron count reevaluation in the myenteric plexus of chagasic megacolon after morphometric neuron analysis. *Virchows Arch* 2001;438(3):254–8.
42. [b] da Silveira AB, D'Avila Reis D, de Oliveira EC, Neto SG, Luquetti, AO, Poole D, Correa-Oliveira R, Furness JB (2007) Neurochemical coding of the enteric nervous system in chagasic patients with megacolon. *Dig Dis Sci* 52:2877–2883.
43. Nascimento, RD, Martins, PR, De Souza Lisboa, A, Adad, SJ, Da Silveira, ABM, Reis, Dd. An imbalance between substance P and vasoactive intestinal polypeptide might contribute to the immunopathology of megaesophagus after *Trypanosoma cruzi* infection. *Hum Pathol* 2013;44(2):269-76.
44. Tanowitz, HB, Kirchoff, LV, Simon, D, Morris, SA, Weiss, LM, Wittner, M. Chagas disease. *Clin Microbiol Rev* 1992;5(4): 400-419.
45. Moreira, NM, Santos, FDN, Toledo, MJO, Moraes, SMF, Araújo, EJA, Sant'Ana, DMG, Araújo, SM. Moderate physical exercise reduces parasitaemia and protects colonic myenteric neurons in mice infected with *Trypanosoma cruzi*. *Int J Exp Path* 2013;94:426-435.
46. Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. *J Gastroenterol* 2003;38:421–30.
47. Ekblad E, Bauer AJ. Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity. *Neurogastroenterol Motil* 2004;16(Suppl 1):123–128.
48. Breneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Peptides* 2007;28:1720–1726
49. Di Giovangiulio, M, Verheijden, S, Bosmans, G, Stakenborg, N, et al. The neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease. *Frontiers in Immunology* 2015;6:590. doi: 10.3389/fimmu.2015.00590

50. Furness JB, Alex G, Clark MJ, Lal VV. Morphologies and projections of defined classes of neurons in the submucosa of the guinea-pig small intestine. *Anat Rec A* 2003; 272:475–483.
51. Dutra, WO, Menezes, CAS, Magalhães, LMD, Gollob, KJ. Immunoregulatory networks in human Chagas disease. *Parasite Immunology* 2014;36:377-387.
52. Buttow NC, Zucoloto S, Espreafico EM, Gama P, Alvares EP. Substance P enhances neuronal area and epithelial cell proliferation after colon denervation in rats. *Dig Dis Sci* 2003;48(10):2069-76.

Table 1. Primary and secondary antibodies used for the immunofluorescence technique.

ANTIBODY	SPECIES	DILUTION	MANUFACTURER	CODE
nNOS	Rabbit	1:1000	Santa Cruz	SC8309
VIP	Rabbit	1:200	ABCAM	AB8556
SP	Rabbit	1:1000	Millipore	AB1566
MYOSIN-V	Rabbit	1:1000	Buttow, et al. ⁵²	-----
ALEXA FLUOR 568 ANTI-RABBIT	Donkey	1:500	Invitogen	A100042

nNOS (neuronal nitric oxide synthase); VIP (vasoactive intestinal peptide); SP (substance P).




Figure 1. Flowchart showing the method used in the study. (A) Experimental groups, (B) Aspirin (ASA) treatment protocol performed during the acute phase (ASA_{Early}) of infection with *Trypanosoma cruzi*, (C) ASA treatment protocol performed during the chronic phase (ASA_{Delayed}) of infection with *T. cruzi*, and (D) Parasitemia curve for male Swiss mice infected with *T. cruzi* (Y strain) and treated with ASA during the acute phase (ASA_{Early}) of the infection. *p < 0.05 compared to the infected group (Mann-Whitney's test).




Figure 2. Evaluation of inflammatory infiltrate in uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and treated with aspirin (ASA). (A) Quantification of inflammatory infiltrate present on the colonic wall after histopathological analysis, (B) Photomicrography showing absence of inflammatory foci in uninfected mice, (C) Intense inflammatory foci presence (see arrow head) in PBS-treated-mice infected with *T. cruzi*, (D) Reduction of inflammatory foci (see arrow head) ASA_{Early}-treated-mice infected with *T. cruzi*, (E) Reduction of inflammatory foci (see arrow head) in ASA_{Delayed}-treated-mice infected with *T. cruzi*. # $p < 0.05$ compared to uninfected PBS-treated-group. * $p < 0.05$ compared to infected PBS-treated-group. ANOVA one-way, followed by Tukey's post-test.




Figure 3. Morphoquantitative and morphometric evaluation of myosin-V⁺ myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) General myenteric neuronal population density (myosin- V⁺), (B) Cell body area of the general myenteric neuronal population, (C) to (F) Immunofluorescence photomicrographies showing myenteric neurons (see arrow heads) in the colon of uninfected mice, infected with *T. cruzi* (Y strain) and treated with ASA during the acute (ASA_{Early}) or chronic (ASA_{Delayed}) phases of the infection. #p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. +p < 0.05 compared to uninfected ASA-treated-groups. †p < 0.05 compared to infected ASA-treated-groups. ‡p < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test.




Figure 4. Morphoquantitative and morphometric evaluation of nitroergic myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) Nitroergic myenteric neuronal population density, (B) Cell body area of the nitroergic myenteric neuronal population, (C) to (F) Immunofluorescence photomicrographies showing myenteric neurons (see arrow heads) in the colon of uninfected mice, infected with *T. cruzi* (Y strain) and treated with ASA during the acute (ASA_{Early}) or chronic (ASA_{Delayed}) phases of the infection. [#]p < 0.05 compared to the uninfected PBS-treated-group. ^{*}p < 0.05 compared to the infected PBS-treated-group. ^{*}p < 0.05 compared to uninfected ASA-treated-groups. ^fp < 0.05 compared to infected ASA-treated-groups. ^τp < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test.




Figure 5. Morphoquantitative and morphometric evaluation of VIPergic myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) VIPergic myenteric neuronal population density, (B) Cell body area of the VIPergic myenteric neuronal population, (C) to (F) Immunofluorescence photomicrographies showing myenteric neurons (see arrow heads) in the colon of uninfected mice, infected with *T. cruzi* (Y strain) and treated with ASA during the acute (ASA_{Early}) or chronic (ASA_{Delayed}) phases of the infection. [#]p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. ^{*}p < 0.05 compared to uninfected ASA-treated-groups. ^fp < 0.05 compared to infected ASA-treated-groups. ^τp < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test.




Figure 6. Morphoquantitative, morphometric, and physiological evaluation of myenteric neurons of uninfected mice, mice infected with *Trypanosoma cruzi* (Y strain) and mice treated with aspirin (ASA). (A) Cholinergic myenteric neuron population density, (B) Gastrointestinal transit evaluation, (C) to (D) Varicosities area of VIP and substance P (SP) producing nerve fibers, (E) Bright field intensity of varicosities containing SP. #p < 0.05 compared to the uninfected PBS-treated-group. *p < 0.05 compared to the infected PBS-treated-group. +p < 0.05 compared to uninfected ASA-treated-groups. †p < 0.05 compared to infected ASA-treated-groups. ‡p < 0.05 comparison between the two ASA-treated-groups (uninfected or infected). ANOVA one-way followed by Tukey's post-test.

CONCLUSÃO

Baseados na hipótese de que o tratamento com aspirina em baixas doses seria eficiente para controle da neuropatia colônica induzida pela infecção com *T. cruzi*, em camundongos, e que os efeitos terapêuticos seriam benéficos para os neurônios do plexo mientérico tornou-se um guia para a realização deste trabalho experimental. Conclui-se, portanto, que a hipótese inicial era verdadeira.

O tratamento com ASA na dose de 20 mg/kg durante a fase aguda da infecção por *T. cruzi* foi capaz de reduzir significativamente a parasitemia, fato este não observado no grupo ASA_{Delayed}. Devido a esse efeito antiparasitário demonstrado no grupo ASA_{Early}, foi possível verificar uma relação entre a carga parasitária e as lesões que se manifestam na fase crônica da infecção: redução na quantidade de focos inflamatórios; preservação estrutural e quantitativa dos neurônios do plexo mientérico colônico e restabelecimento da função intestinal. Como os camundongos do grupo ASA_{Delayed} não tiveram alteração nos parâmetros parasitológicos, pode-se inferir que os benefícios terapêuticos oriundos da administração de ASA, possivelmente podem estar relacionados com a redução do processo inflamatório.

Desse modo, o tratamento com ASA mostrou-se eficaz para reduzir as alterações teciduais e celulares que acompanham as manifestações clínicas da DC. Entretanto, benefícios maiores são adquiridos quando o tratamento ocorre precocemente, nos períodos iniciais do processo infeccioso. Portanto, sugere-se a realização de trabalhos que possuam um maior tempo de tratamento com ASA, iniciando na fase aguda da infecção, bem como a inclusão de métodos fisiológicos como a manometria que possam avaliar as alterações da motilidade do cólon.

REFERÊNCIAS

- Abdalla, GK, Faria, GEL, Silva, KT, Castro, ECC, Reis, MA, Michelin, MA. *Trypanosoma cruzi*: the role of PGE2 in immune response during the acute phase of experimental infection. *Experimental Parasitology* 2008; 118:514-521.
- Adad SJ, Cançado CG, Etchebehere RM, Teixeira VP, Gomes UA, Chapadeiro E, et al. Neuron count reevaluation in the myenteric plexus of chagasic megacolon after morphometric neuron analysis. *Virchows Arch.* 2001; 438(3):254–8.
- Afonso, AM, Ebell, MH, Tarleton, RL. A systematic review of high quality diagnostic tests for Chagas disease. *Plos Negl. Trop. Dis.* 2012; 6(11):e1881.
- Andreollo, NA, Malafaia, O. Os 100 anos da doença de Chagas no Brasil. *Arq. Bras. Cir. Dis.* 2009;22(4):185-191.
- Arakawa, T, Watanabe, T, Tanigawa, T, Tominaga, K, Otani, K, Nadatani, Y, Fujiwara, Y. Small intestinal injury caused by NSAIDs/aspirin: finding new from old. *Curr Med Chem* 2012; 19(1):77-81.
- Argov S, Jaffe CL, Krupp M, Slor H and Shoenfeld Y. Autoantibody production by patients infected with Leishmania. *Clin Exp Immunol* 1989; 76: 190-197.
- Asanuma, M, Nishibayashi-Asanuma, S, Miyazaki, I, Kohno, M, Ogawa, N. Neuroprotective effects on non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. *Journal of Neurochemistry* 2001; 76:1895-1904.
- Barrias, ES, Carvalho, TMU, Souza, W. *Trypanosoma cruzi*: Entry into Mammalian Host Cells and Parasitophorous Vacuole Formation. *Front. Immunol.* 2013;4: PMC3730053
- Bern CM, Montgomery SP. An estimate of the burden of Chagas disease in the United States. *Clin Infect Dis* 2009; 49: e52–54.
- Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Doenças infecciosas e parasitárias: guia de bolso / Ministério da Saúde, Brasília: Ministério da Saúde, 2010. 444 p.

Braz, LM, Amato-Neto, V, Okay, TS. Reactivation of *Trypanosoma cruzi* infection in immunosuppressed patients: contributions for the laboratorial diagnosis standardization. *Rev. Inst. Med. Trop. São Paulo* 2008; 50(1):65-6.

Brehmer A. Structure of enteric neurons. *Adv Anat Embryol Cell Biol* 2006; 186:1–94

Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with *Trypanosoma cruzi*. *Rev Inst Med Trop* 1962; 4: 389–96.

Brener Z. Life cycle of *Trypanosoma cruzi*. *Rev.Inst. Med. Trop. São Paulo* 1971;13:171-78.

Brenneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Peptides* 2007; 28:1720–1726

Caetano, LC, Prado Jr, JC, Toldo, MPA, Abrahão, AAC. *Trypanosoma cruzi*: do different sylvatic strains trigger distinct immune responses? *Experimental Parasitology* 2010; 124:219-224.

Campos CF, Cangussú SD, Duz ALC, Cartelle CT, Noviello MdL, Veloso VM, et al. Enteric Neuronal Damage, Intramuscular Denervation and Smooth Muscle Phenotype Changes as Mechanisms of Chagasic Megacolon: Evidence from a Long-Term Murine Model of *Trypanosoma cruzi* Infection. *Plos ONE* 2016;11(4): e0153038. doi:10.1371/journal.pone.0153038.

Cillari, E., et al. *In vivo* and *in vitro* cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. *Cytokine* 1995; 7:740–745.

Clayton J. Chagas disease 101. *Nature* 2010; 465:S4–S5.

Conlin, VS, Wu, X, Nguyen,C, Vallance, BA, Buchan, AM, Boyer, L, Jacobson, K. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with *Citrobacter rodentium*-induced colitis. *Am. J. Physiol. Gastrointest. Liver. Physiol.* 2009;297(4):G735-50.

Correa-Oliveira R, Gomes J, Lemos EM, Cardoso GM, Reis DD, Adad S, Crema E, Martins-Filho OA, Costa MO, Gazzinelli G, Bahia-Oliveira LM. The role of the

immune response on the development of severe clinical forms of human Chagas disease. *Mem Inst Oswaldo Cruz* 1999;94 (Suppl. I): 253-255.

Cossentini, LA, Da Silva, RV, Yamada-Ogatta, SF, Yamauchi, LM, Araújo, EJA, Pinge-Filho, P. Aspirin treatment exacerbates oral infections by *Trypanosoma cruzi*. *Experimental Parasitology* 2016; 164:64-70.

Coura, JR, Borges-Pereira, J. Chagas disease: 100 years after its discovery. A systemic review. *Acta Tropica* 2010; 115:5-13.

Coura, JR, Dias, JCP. Epidemiology, control and surveillance of Chagas disease – 100 years after its discovery. *Mem. Inst. Oswaldo Cruz* 2009; 104(Suppl 1):31-40.

Coura, JR, Viña, PA. Chagas disease: a new worldwide challenge. *Nature* 2010.

Cunha-Neto, E, Durtanti, M, Gruber, A, Zingales, B, De Messias, I, et al. Autoimmunity in Chagas disease cardiopathy: Biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant *Trypanosoma cruzi* antigen. *Proc. Natl. Acad. Sci. USA* 1995; 92:3541-3545.

Cunha-Neto, E, Chevillard, C. Chagas disease cardiomyopathy: immunopathology and genetics. *Mediators of Inflammation* 2014; Article ID 683230.

Da Silveira AB, Arantes RM, Vago AR, et al. Comparative study of the presence of *Trypanosoma cruzi* kDNA, inflammation and denervation in chagasic patients with and without megacolon. *Parasitology* 2005; 131:627- 34.

Da Silveira, ABM, Lemos, EM, Adad, SJ, Correa-Oliveira, R, Furness, JB, Reis, DD. Megacolon in Chagas disease: a study of inflammatory cells, enteric nerves, and glial cells. *Human Pathology* 2007; 38:1256-1264.

Da Silveira AB, D'Avila Reis D, de Oliveira EC, Neto SG, Luquetti, AO, Poole D, Correa-Oliveira R, Furness JB (2007) Neurochemical coding of the enteric nervous system in chagasic patients with megacolon. *Dig Dis Sci* 52:2877–2883.

Daniel-Ribeiro CT and Zanini G. Autoimmunity and malaria: what are they doing together? *Acta Trop* 2000;76: 205-221.

De Moraes, KCM, et al. Role of cyclooxygenase-2 in *Trypanosoma cruzi* survival in the early stages of parasite host-cell interaction. *Mem. Inst. Oswaldo Cruz* 2015;110(2):181-191.

Delgado, M, Ganea, D. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP *in vitro* and *in vivo*. *Arch. Physiol. Biochem.* 2001;109(4):377-82.

Dias JCP. Natural history of Chagas' disease. *Arq Bras Cardiol* 1995; 65:359–66.

Durand JL, Mukherjee S, Commodari F, De Souza AP, Zhao D, Machado FS, Tanowitz HB, Jelicks LA. Role of NO synthase in the development of *Trypanosoma cruzi*-induced cardiomyopathy in mice. *Am J Trop Med Hyg.* 2009;80(5):782–787.

Dutra WO, Menezes CA, Villani FN, da Costa GC, da Silveira AB, Reis D, Gollob KJ. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. *Mem Inst Oswaldo Cruz* 2009; 104(Suppl 1):208–218.

Dutra, WO, Menezes, CAS, Magalhães, LMD, Gollob, KJ. Immunoregulatory networks in human Chagas disease. *Parasite Immunology* 2014; 36:377-387.

Ekblad E, Bauer AJ. Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity. *Neurogastroenterol Motil.* 2004;16(Suppl 1):123–128.

Epting, CL, Coates, BM, Engman, DM. Molecular mechanisms of host cell invasion by *Trypanosoma cruzi*. *Exp. Parasitol.* 2010; 126(3):283-91.

FREIRE-DE-LIMA, CG, XIAO, YQ, GARDAI, SJ, BRATTON, DL SCHIEMANN, WP and HENSON, PM. Apoptotic cells, through transforming growth factor-beta, coordinately induce antiinflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. *J Biol Chem* 2006; 281, 38376-84.

Freire De Lima, CG, Nascimento, DO, Soares, MBP., Bozza, PT, Castro Faria Neto, HC, De Mello, FG, Dos Reis, GA, Lopes, MF. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. *Nature* 2000; 403, 199–203.

Fundação Oswaldo Cruz - Fiocruz. 2013. [Accessed on February 5, 2016.] Available from URL: <http://www.agencia.fiocruz.br/doen%C3%A7a-de-chagas>

Furness JB, Alex G, Clark MJ, Lal VV. Morphologies and projections of defined classes of neurons in the submucosa of the guinea-pig small intestine. *Anat Rec A* 2003; 272:475–483.

Furness JB. The enteric nervous system. Blackwell, Oxford. 2006

Furness, JB. The enteric nervous system and neurogastroenterology. *Gastroenterol. Hepatol.* 2012; doi:10.1038/nrgastro.2012.32

GANZINELLI, S., BORDA, E., JOENSEN, L. and STERIN-BORDA, L. Chagasic antibodies induce cardiac COX-2/iNOS mRNA expression with PGE2/NO production. *Int J Cardiol* 2009; 134: 212-23.

Giorgio, R, Camilleri, M. Human enteric neuropathies: morphology and molecular pathology. *Neurogastroenterol. Motil.* 2004; 16:515-531.

Gontijo, ED, Galvão, LMC, Eloi-Santos, S. Chagas disease: Criteria of cure and prognosis. 1999; 94(suppl):357-362.

GRAUERT, MR, HOUSSAYER, M, HONTEBEYRIE-JOSKOWCIZ, M. *Trypanosoma cruzi* infection enhances polyreactivity antibody response in an acute case of human Chagas' disease. *Clinical and Experimental Immunology* 1983;93:85-92.

Harris, S.G., Padilla, J., Koumas, L., Ray, D., Phipps, R.P. Prostaglandins as modulators of immunity. *Trends Immunol.* 2002; 23:144– 150.

HOFFLIN, JM, SADLER, RH, ARAUJO, FG, PAGE, WE, REMINGTON, JS. Laboratory-acquired Chagas disease. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 1987; 81:437-440.

Jabari, S, Da Silveira, ABM, Oliveira, EC, Neto, SG, Quint, K, Neuhuber, W, Brehmer, A. Partial, selective survival of nitrergic neurons in chagasic megacolon. *Histochem Cell Biol* 2011; 135:47-57.

Jabari, S, Da Silveira, ABM, Oliveira, EC, Neto, SG, Quint, K, Neuhuber, W, Brehmer, A. Selective survival of calretinin- and vasoactive-intestinalpeptide-containing nerve elements in human chagasic submucosa and mucosa. *Cell Tissues Res* 2012; 349:473-481.

Jabari, S, Oliveira, EC, Brehmer, A, Da Silveira, ABM. Chagasic megacolon: enteric neurons and related structures. *Histochem Cell Biol* 2014; 142:235-244.

Koeberle, F. The causation and importance of nervous lesions in American trypanosomiasis. *Bull. World Health Organ.* 1970; 42:739–743.

Maifrino, LBM, Liberti, EA, Watanabe, IS, Souza, RR. Morphometry and acetylcholinesterase activity of the myenteric neurons of the mouse colon in the chronic phase of experimental *Trypanosoma cruzi* infection. *Am J Trop Med Hyg* 1999; 60(5):721-725.

Malvezi, AD, Da Silva, RV, Panis, C, Yamauchi, LM, Lovo-Martins, MI, Zanluqui, NG, et al. Aspirin modulates innate inflammatory response and inhibits the entry of *Trypanosoma cruzi* in mouse peritoneal macrophages. *Mediators of Inflammation* 2014; 580919. doi: 10.1155/2014/580919.

Malvezi, AD, Panis, C, Da Silva, RV, Freitas, RC, Lovo-Martins, MI, Tatakihara, VL, et al. Inhibition of Cyclooxygenase-1 and Cyclooxygenase-2 Impairs *Trypanosoma cruzi* entry into cardiac cells and promotes differential modulation of the inflammatory response. *Antimicrobial Agents and Chemotherapy* 2014; 10:6157-6164.

Martins-Melo FR, Ramos AN, Alencar CH, Heukelbach J. Mortality related to Chagas disease and HIV/AIDS coinfection in Brazil. *J Tropical Med.* 2012; 2012:1–4.

Matsuda, NM, Miller, MS, SM, Evora, PRB. The chronic gastrointestinal manifestations of Chagas disease. *Clinics* 2009; 64(12):1219-24.

Maya, J.D., Rodríguez, A., Pino, L., Pabon, A., Ferreira, J., Pavani, M., Repetto, Y., Morello, A. Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in *Trypanosoma cruzi*. *Biol. Res.* 2004; 37: 61–69.

- Maya, JD, Cassels, BK, Iturriaga-Vásquez, P, et al. Mode of action of natural and synthetic drugs against *Trypanosoma cruzi* and their interactions with the mammalian host. *Comparative Biochemistry and Physiology*. 2007; 146:601-620.
- Maya, JD, Orellana, M, Ferreira, J, Kemmerling, U, Lopez-Muños, R, Morello, A. Chagas disease: presente status of pathogenic mechanisms and chemotherapy. *Biol Res* 2010; 43:323-331.
- McCormick, TS, Rowland, EC. *Trypanosoma cruzi*: cross-reactive anti-heart autoantibodies produced during infection in mice. *Exp. Parasitol* 1989; 69(4):393-401.
- Medei, EH. et al. Envolvimento de auto-anticorpos na fisiopatologia da Doença de Chagas. *Arquivos Brasileiros de Cardiologia*, 2008; 91:281-286.
- Medeiros, R, Kitazawa, M, Passos, GF, Baglietto-Vargas, D, Cheng, D. et al. Aspirin-Triggered Lipoxin A4 stimulates alternative activation of micróglia and reduces Alzheimer disease-like pathology in mice. *The American Journal of Pathology* 2013;182(5).
- Melo, RC, Brener, Z. Tissue tropismo of diferente *Trypanosoma cruzi* strains. *J. Parasitol*. 1978;64(3):475-82.
- Michailowsky, V, Silva, NM, Rocha, CD, Vieira, LQ, Lannes-Vieira, J, Gazzinelli, RT. Pivotal role of interleukin-12 and interferon gama axis in controlling tissue parasitismo and inflammation in the heart and central nervous system during *Trypanosoma cruzi* infection. *American Journal of Pathology* 2001; 109(5):1723-1733.
- Molina-Bérríos, A, Campos-Estrada, C, Henriquez, N, Faúndez, M, Torres, G, et al. Protective role of acetylsalicylic acid in experimental *Trypanosoma cruzi* infection: evidence of 15-epi-Lipoxin A4-Mediated effect. *PLoS Negl Trop Dis* 2013;7(4):e2173.
- Molina-Bérríos, A, Campos-Estrada, C, Lapier, M, Duaso, J, Kemmerling, U, et al. Protection of vascular endothelium by aspirin in a murine modelo f chronic Chagas disease. *Parasitol Res* 2013; 112:2731-2739.

Montgomery, SP, Starr, MC, Cantey, PT, Edwards, MS, Meymandi, SK. Neglected parasitic infections in the United States: Chagas disease. *Am. J. Trop. Med. Hyg.* 2014; 90(5):814-818.

Moreira, NM, Sant'Ana, DMG, Araújo, EJA, Toledo, MJO, Gomes, ML, Araújo, SM. Neuronal changes caused by *Trypanosoma cruzi*: an experimental model. *Anais da Academia Brasileira de Ciências* 2011; 83(2):545-555.

Moreira, NM, Santos, FDN, Toledo, MJO, Moraes, SMF, Araújo, EJA, Sant'Ana, DMG, Araújo, SM. Moderate physical exercise reduces parasitaemia and protects colonic myenteric neurons in mice infected with *Trypanosoma cruzi*. *Int. J. Exp. Path.* 2013; 94:426-435.

Moreira, NM, Zanoni, JN, Dalálio, MMO, Araújo, EJA, Braga, CF, Araújo, SM. Physical exercise protects myenteric neurons and reduces parasitemia in *Trypanosoma cruzi* infection. *Experimental Parasitology* 2014; 141:68-74.

Moro, MA, De Alba, J, Cárdenas, A, De Cristóbal, J, Leza, JC, et al. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain slices. *Neuropharmacology* 2000; 39(7):1309-18.

Morris, T, Stables, M, Hobbs, A, Souza, P, Colville-Nash, P, Warner, T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. *The Journal of Immunology* 2009;183(3):2089-2096.

Mukherjee, S, Machado, FS, Huang, H, Oz, HS, Jelicks, LO, Prado, CM, et al. Aspirin treatment of mice infected with *Trypanosoma cruzi* and implications for the pathogenesis of Chagas disease. *Plos ONE* 2011;6(2):e16959.

Murphy EM, Defontgalland D, Costa M, Brookes SJ, Wattchow DA. Quantification of subclasses of human colonic myenteric neurons by immunoreactivity to Hu, choline acetyltransferase and nitric oxide synthase. *Neurogastroenterol. Motil.* 2007; 19:126–134

Nascimento, RD, Martins, PR, De Souza Lisboa, A, Adad, SJ, Da Silveira, ABM, Reis, Dd. An imbalance between substance P and vasoactive intestinal polypeptide

might contribute to the immunopathology of megaesophagus after *Trypanosoma cruzi* infection. *Hum Pathol* 2013; 44(2):269-76.

Nogueira-Paiva, NC, Fonseca, KS, Vieira, PMA, Diniz, LF, Caldas, IS, et al. Myenteric plexus is differentially affected by infection with distinct *Trypanosoma cruzi* strains in Beagle dogs. *Mem. Inst. Oswaldo Cruz* 2014; 109:51-60.

Nunes, MCP, Dones, W, Morillo, CA, Encina, JJ, Ribeiro, AL, et al. Chagas disease: an overview of clinical and epidemiological aspects. *Journal of the American College of Cardiology* 2013; 62(9):767-76.

Osorio, L. et al. Virulence factors of *Trypanosoma cruzi*: who is who? *Microbes Infect.* 2012; 14(15):1390-1402.

Pavanelli, WR, Gutierrez, FRS, Mariano, FS, Prado, CM, Ferreira, BR, et al. 5-Lipoxygenase is a key determinant of acute myocardial inflammation and mortality during *Trypanosoma cruzi* infection. *Microbes and Infection* 2010; 12:587-597.

Phillips, RJ, Kieffer, EJ, Powley, TL. Aging of the myenteric plexus: neuronal loss is specific to cholinergic neurons. *Auton Neurosci* 2003; 106(2):69-83.

Pinazo, MJ, Guerrero, L, Posada, E, et al. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patient with chronic Chagas disease. *Antimicrobial Agents and Chemotherapy.* 2013; 57:390-395.

Pinazo, MJ; Lacima, G; Elizalde, JI, et al. Characterization of digestive involvement in patients with chronic *T. cruzi* infection in Barcelona, Spain. *PLoS Negl Trop Dis* 8(8): e3105. doi:10.1371/journal.pntd.0003105

Pinge-Filho, P., Tadokoro, C. E. and Abrahamsohn, I. A.: Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute *Trypanosoma cruzi* infection. *Cell Immunol* 1999;193, 90-8.

Pontes, VMO, Souza Júnior, AS, Cruz, FMT, et al. Reações adversas em pacientes com doença de Chagas tratados com benznidazol, no Estado do Ceará. *Revista da Sociedade Brasileira de Medicina Tropical.* 2010; 43(2): 182-187.

Poveda C, Fresno M, Girones N, Martins-Filho OA, Ramirez JD, et al. Cytokine Profiling in Chagas Disease: Towards Understanding the Association with Infecting *Trypanosoma cruzi* Discrete Typing Units (A BENEFIT TRIAL Sub-Study). *PLoS ONE* 2014; 9(3): e91154.

Rassi A, Amato Neto V, de Siqueira AF, Ferriolli Filho F, Amato VS, et al. Protective effect of benznidazole against parasite reactivation in patients chronically infected with *Trypanosoma cruzi* and treated with corticoids for associated diseases. *Rev Soc Bras Med Trop* 1999; 32: 475–482

Rassi Jr, A, Rassi, A, Marin-Neto, JA. Chagas disease. *Lancet* 2010; 375:1388-402.

Rassi A, Rezende JM, Luquetti AO, et al. Clinical phases and forms of Chagas disease. In: Telleria J, Tibayrenc M, editors. American trypanosomiasis (Chagas disease). One hundred years of research. 1st edition. Burlington (MA): Elsevier Inc; 2010. p. 709–41.

Rassi Jr, A, Rassi, A, Rezende, JM. American Trypanosomiasis (Chagas disease). *Infect. Dis. Clin. N. Am.* 2012; 26:275-291.

Ribeiro-dos-Santos R, Marquez JO, Von Gal Furtado CC, Ramos de Oliveira JC, Martins AR and Koberle F. Antibodies against neurons in chronic Chagas' disease. *Tropenmed Parasitol* 1979; 30: 19-23.

Rios-Ibarra, CP, Losano-Sepulveda, S, Muñoz-Espinosa, S, Rincón-Sanchez, AR, Cordova-Fletes, C, Rivas-Estilla, AM. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. *Arch Virol* 2014; 159(12):3321-8.

Romanha, AJ, Alves, RO, Murta, S.M., Silva, JS, Ropert, C, Gazzinelli, RT. Experimental chemotherapy against *Trypanosoma cruzi* infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. *J. Infect. Dis.* 2002; 186: 823–828.

Sasseli, V, Pachnis, V, Burns, AJ. The enteric nervous system. *Developmental Biology* 2012; 366:64-73.

Soares, MBP, Pontes-de-Carvalho, L, Ribeiro-dos-Santos, R. The pathogenesis of Chagas disease: when autoimmune and parasite-specific immune response meet. *An. Acad. Bras. Ciênc.* 2001; 73(4):547-559.

Souza, W, Carvalho, TM, Barrias, ES. Review on *Trypanosoma cruzi*: Host Cell Interaction. *Int. J. Cell Biol.* 2010; 295394. doi: 10.1155/2010/295394

Stoppani, AOM. Quimioterapia de La enfermedad de Chagas. *Medicina.* 1999; 59: 147-165.

Tafari, L., T. A. Maria, and E. R. Lopes. Pathogenesis of lesions of the autonomic nervous system of the mouse in experimental acute Chagas' disease. Light and electron microscope studies. *Am. J. Trop. Med. Hyg.* 1970; 19:405–417.

Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. *J Gastroenterol.* 2003; 38:421–30.

Tanowitz, HB, Kirchhoff, LV, Simon, D, Morris, SA, Weiss, LM, Wittner, M. Chagas disease. *Clin Microbiol Rev.* 1992; 5(4): 400-419.

Tatakihara VL, Cecchini R, Borges CL, Malvezi AD, Graca-de Souza VK, et al. Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine *Trypanosoma cruzi* infection. *FEMS Immunol Med Microbiol* 2008; 52:47-58.

Teixeira, ARL, Nascimento, RJ, Sturm, NR. Evolution and pathology in Chagas disease – a Review. *Mem. Inst. Oswaldo Cruz* 2006; 101(5):463-491.

Teixeira, ARL, Pimentel, F, Cordeiro, C. The pathology of Chagas disease, p. 2009;110–121. In A. R. L. Teixeira, M. C. Vinaud, and A. M. Castro (ed.), *Emerging Chagas disease*, 1st ed. Bentham Science Publishers, New York, NY.

Teixeira, ARL, Hecht, MM, Guimaro, MC, Souza, AO, Nitz, N. Pathogenesis of Chagas disease: parasite persistence and autoimmunity. *Clinical Microbiology Reviews* 2011; 24:592-630.

Torres, C. M. Myocytolysis and fibrosis of the myocardium in Chagas disease. *Mem. Inst. Oswaldo Cruz* 1960; 58:161–182.

Turrens, JF, Watts Jr, BP, Zhong, L, Docampo, R. Inhibition of *Trypanosoma cruzi* and *T. brucei* NADH fumarate reductase by benznidazole and anthelmintic imidazole derivatives. *Mol. Biochem. Parasitol.* 1996; 82:125–129.

Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. *Acta Trop.* 2010; 115:55–68.

Van Voorhis WC and Eisen H. Fl-160. A surface antigen of *Trypanosoma cruzi* that mimics mammalian nervous tissues. *J Exp Med* 1989; 169: 641-652.

Vazquez, BP, Vazquez, TP, Miguel, CB, Rodrigues, WF, Mendes, MT, Oliveira, CJF, Chica, JEL. Inflammatory responses and intestinal injury development during acute *Trypanosoma cruzi* infection are associated with the parasite load. *Parasites & Vectors* 2015; 8:206.

Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, de LaFuente E, Ferrufino L, Bowman NM, Pinedo-Cancino V, Levy MZ, Steurer F, Todd CW, Kirchhoff LV, Cabrera L, Verastegui M, Bern C. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic *Trypanosoma cruzi* infection. *Am J Trop Med Hyg* 2009; 80: 410-415.

WHO. World Health Organization. Chagas disease (American trypanosomiasis) Available in: <http://www.who.int/mediacentre/factsheets/fs340/en/> . Accessed 02-08-2014.

Zingales, B, Miles, MA, Moraes, CB, Luquetti, A, Guhl, F, Schijman, A, Ribeiro, I. Drug discovery for Chagas disease should consider *Typanosoma cruzi* strain diversity. *Men. Inst. Oswaldo Cruz* 2014; 109(6):828-833.

ANEXOS

A
Aprovação da Comissão de Ética no Uso de Animais da Universidade Estadual de Londrina (CEUA/UUEL) protocolo 156/2012 e processo 7371.2012.56.



Universidade
Estadual de Londrina

COMISSÃO DE ÉTICA NO USO DE ANIMAIS

OF. CIRC. CEUA Nº 156/12

Londrina, 25 de Junho de 2012

Prezada Pesquisadora,

A CEUA/UUEL, reunida em 19 de Junho de 2012, reavaliou o projeto de pesquisa intitulado "*Análise dos efeitos do tratamento com aspirina sobre o desenvolvimento de neuropatia entérica de camundongos infectados com Trypanosoma Cruzi*", processo registrado na CEUA sob nº 7371.2012.56, pesquisa do Centro de Ciências Biológicas, desenvolvido sob sua responsabilidade. Esclarecidos os aspectos metodológicos solicitados, o projeto está aprovado para execução entendendo-se que os princípios éticos postulados pelo Conselho Nacional de Controle da Experimentação Animal estão respeitados.

Serão utilizados 192 camundongos da raça Suíços com idade de 60 dias, machos, com procedência do Biotério Central CCB-UUEL. Neste projeto será avaliado se o uso de aspirina, uma droga antiinflamatória não esteroideal (AINES) convencional, durante a fase aguda da infecção experimental causada por *Trypanosoma cruzi* (cepa y) interfere no desenvolvimento da neuropatia entérica chagásica observada na fase crônica da infecção. Para isto camundongos que não serão infectados serão tratado com PBS sem aspirina (G1), camundongos não infectados será tratado com a Aspirina (G2), camundongos infectados serão tratados com PBS (G3) e camundongos infectados serão tratados com aspirina (G4). Os camundongos receberão *T. cruzi* para indução de uma fase crônica e serão tratados com Benznidazol nos dias 11, 16 e 18 após a infecção. O tratamento com a aspirina será iniciado no 20º dia após a infecção, sendo o tratamento diário e 75 dia após a infecção os camundongos serão eutanasiados. Os colóns dos animais serão coletados e analisados quanto a quantidade de neurônios mioentéricos, também será realizada a análise morfométrica dos neurônios e dosagem de citocinas. O projeto está previsto para ser desenvolvido em 24 meses

Cumpra orientar que caso pretendam-se quaisquer alterações no protocolo experimental aprovado, deve-se submeter o novo protocolo à apreciação da CEUA/UUEL anteriormente à execução das modificações. Sem mais para o momento, subscrevo-me. Cordialmente,

Waldiceu Esp. Verrri Junior
Prof. Dr. Waldiceu Aparecido Verrri Junior
Coordenador da CEUA/UUEL

Ilmo. Sr.

Prof. Dr. Eduardo José de Almeida Araújo

Coordenadora do Projeto

Departamento de Histologia

Centro de Ciências Biológicas

Com cópia para Srª Égle Maria de Sousa (Chefe da DCA/PROPPG) e Prof. Luiz Carlos Juliani (Diretor do Biotério Central da UEL).

Campus Universitário: Rodovia Cto. Garcia Cid (PR 445), km 389 - Fone (843) 3371-1000 PABX - Fax 3328-4440 - Caixa Postal 6.201 - CEP 86051-990 - Internet <http://www.uel.br>
Hospital Universitário/Centro de Ciências da Saúde: Av. Robert Koch, 60 - Vila Operária - Fone (843) 381-2000 PABX - Fax 337-4841 e 337-7495 - Caixa Postal 791 - CEP 86038-440

LONDRINA - PARANÁ - BRASIL

26 JUN 2012

B
CERTIFICADO DE SUBMISSÃO DO MANUSCRITO

☰ Neurogastroenterology and Motility

Submission Confirmation

Print

Thank you for your submission

Submitted to

Neurogastroenterology and Motility

Manuscript ID

NMO-00254-2016

Title

Myenteric neuroprotective role of aspirin in acute and chronic experimental infections with *Trypanosoma cruzi*

Authors

Yasuo Oda, Juliano
de Oliveira Belém, Monica
Massi Carlos, Thalita
Gouveia, Rafael
Martins Moreira, Neide
Massocatto, Cristina L.
Marques de Araújo, Silvana
Sant'Ana, Debora
Buttow, Nilza C.
Pinge Filho, Phileno
Araújo, Eduardo José

Date Submitted

13-Jul-2016

Author Dashboard

C

NORMAS DA REVISTA **Neurogastroenterology & Motility** (Fator de Impacto: 3.587)

1. Author Guidelines

Effective with the 2014 volume, this journal will be published in an online-only format.

PUBLICATION

POLICY

Submission is considered on the conditions that papers are previously unpublished, and are not offered simultaneously elsewhere, that all authors (defined below) have read and approved the content, that authors have declared all competing interests and the work has been conducted under internationally accepted ethical standards after relevant ethical review.

Copyright

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit <http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html>.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal's compliant self-archiving policy please visit: <http://www.wiley.com/go/funderstatement>.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author

Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit <http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html>.

Ethics

The Journal's ethical policies are outlined in the separate document [Ethical Policies of Neurogastroenterology & Motility](#). Submitted work must comply with this policy, which is based on the Committee on Publication Ethics (COPE) guidelines on good publication and comply with their [Code of Conduct](#).

Please note that the journal employs a plagiarism detection system. By submitting your manuscript to the journal you accept that your manuscript may be screened for plagiarism against previously published works.

Accepted Articles

Upon acceptance for publication, all authors must complete and submit

- a [Conflict of Interests Form \(COI\)](#)

Authors are responsible for securing (and funding) permission to use any figures or tables previously published. Accepted papers will not be transferred for publication until these permissions are in place.

SUBMISSION

Neurogastroenterology & *Motility* only accepts submission at <http://mc.manuscriptcentral.com/nmo>. This enables rapid and effective peer review. Contributions will be acknowledged automatically by the editors and assigned a unique manuscript number that must be quoted in correspondence. Papers and Reviews are refereed by experts in the field; the Editors reserve the right to reject an article without review.

Full uploading instructions and support are available online from the submission site via the "Get Help Now" button. Please submit your covering letter or comments to the editor as well as the names of potential referees when prompted online.

Manuscripts that do not meet the formal criteria listed below will be returned for reformatting, which will delay the review process and possible acceptance. Exceptions to these guidelines may be made in certain circumstances, at the discretion of the Editors. If you require an exemption, please indicate this in your cover letter.

Over the past few years, *Neurogastroenterology & Motility* has become one of the leading journals in the field of gastroenterology and related areas of physiology. This is reflected by the steadily increasing number of high-quality manuscripts submitted to the Journal. The length of a manuscript needs to be closely adhered to, with any additional material to be published as supporting information. Authors need not pay for the publication of figures in colour.

Manuscripts that do not meet these formal criteria will be returned for reformatting, which will delay the review process and possible acceptance.

Article types

Original

Original Articles describe the results of basic or clinical studies, clinical trials or significant **Case Reports**. The length of an Original Article should be no longer than **5000** words, excluding acknowledgements and disclosures, references, tables, figures, table legends and figure legends, and to limit the number of figures and tables to a maximum

Articles

of eight in the regular edition of the Journal (e.g. five figures and three tables) in normal circumstances, with any additional material to be published as supporting information.

We work together with Wiley's open access journal, *Clinical Case Reports*, to enable rapid publication of good quality case reports that we are unable to accept for publication in our journal. Authors of case reports rejected by our journal will be offered the option of having their case report, along with any related peer reviews, automatically transferred for consideration by the *Clinical Case Reports* editorial team. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. *Clinical Case Reports* will consider case reports from every clinical discipline and may include clinical images or clinical videos. *Clinical Case Reports* is an open access journal, and article publication fees apply. For more information please go to www.clinicalcasesjournal.com.

Review

Articles

Topical reviews of basic or clinical areas are commissioned by the Reviews Editor. Review Articles are focused topical accounts that highlight new and/or controversial areas. Manuscript length is limited to **5000** words. All Review articles are subject to review by experienced referees. The Journal welcomes un-solicited Reviews, but the Reviews Editor reserves the right to reject these without formal review. As Reviews are commissioned by the Editors far in advance of publication, if you wish to submit a non-commissioned review please contact the Reviews Editor, Gary Mawe (gary.mawe@uvm.edu) for consideration.

Hot

Topics

Manuscripts submitted for the "Hot Topics" section should be no more than **1500** words in total and include only one figure. They will be reviewed and accepted by the Editors on the basis of their outstanding scientific value and the presentation of novel insights into neural control on gut functions in health or disease. "Hot Topics" articles will be only accepted with minor changes. Publication will be in the next available issue with the aim to publish the manuscript about two months after submission. The Editors reserve the right to reject manuscripts without formal review. Rejection for inclusion in the "Hot Topics" section does not disqualify manuscripts for resubmission as an Original Article.

Letters

to

the

Editor

Letters to the Editor offer opinions on papers published in *Neurogastroenterology & Motility*. Text should not exceed **400** words. Letters commenting on papers are sent to the authors of those papers for a response. Letters are selected for their importance, relevance, and originality; not all letters submitted can be published.

Technical

Notes

Technical Notes papers are restricted to a maximum of **1500** words. The manuscript should focus on technique, validation of the technique, and include relevant references and up to two figures.

Book

Reviews

Neurogastroenterology & Motility does not publish Book Reviews.

Revisions

To make it easier for re-review, we encourage authors to make the revisions in their manuscript using a colored font (blue or red) and/or a colored highlighter (yellow). They should also provide a point by point response to the editor of the changes that were made in a letter that describes the requested change and the responses.

The editors have designated two types of revision for manuscripts in the Journal: (i) Minor revisions: these in general require only changes to the manuscript or easily conducted experiments. Revised manuscripts must be submitted in their final form no later than four

weeks of receipt of a revision letter from the Editor. (ii) Major revisions: these require changes to the manuscript and significant additional experiments. Revised manuscripts must be submitted in their final form within three months of receipt of a revision letter from the editor.

In all cases, resubmissions after the allotted time will be considered as new submissions.

Language

Please note that the Journal uses American spelling (e.g. 'esophagus', not 'oesophagus'). Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication. Authors of manuscripts with a poor standard of English will be directed towards the abovementioned editing services.

PRESENTATION

Acceptable file formats

Text: Manuscript should be submitted as one text file in either Word document (.doc), or RTF (.rtf). Manuscripts submitted as PDF (.pdf) will be rejected and delay the submission process.

Tables: Should form an integral part of the text file. Tables submitted as photographs or graphics will be rejected and delay the submission process.

Figures for review: Must be uploaded separately.

Figures for publication: On acceptance, you will be required to upload high resolution graphics files. Unlabelled micrographs (tone) should be supplied as TIFF (.tif), and will not be accepted as PDF (.pdf) format. Labelled micrographs (combination) or charts/ graphs/ diagrams (line) must be supplied as PDF (.pdf) or as EPS (.eps) format and created in vector based software.

Text

Manuscripts should be typed in a standard, easy to read font, either 11 or 12pt in size. Manuscripts should be double-spaced, with 2.5cm (1 inch) margins on all sides and run in one single column. Please ensure that you have turned "track changes off" and removed any reviewing notes from your manuscripts else these will be visible throughout the review process. Place the page number and first author's last name in the upper right-hand corner of each page.

Review articles should be divided onto the following sections and appear in the following order: (1) title page (with short running page heading, title, authors names and affiliations), (2) abstract and keywords, (3) body of the article, (4) acknowledgments, funding, and disclosures; (5) references, (6) tables, (7) figure legends, and (8) figures.

Original articles should be divided into the following sections and appear in the following order: (1) title page (with short running page heading, title, authors names and affiliations) (2) abstract and keywords, (3) introduction, (4) materials and methods, (5) results, (6) discussion, (7) acknowledgments, funding, and disclosures, (8) references, (9) appendices, (10) supporting information, (11) tables, (12) figure legends, and (13) figures.

Title Page

On the title page, provide the complete title and a running title (not to exceed 45 characters and spaces). List each contributor's name and institutional affiliation. Provide the name, postal and e-mail address, fax and telephone number of the contributor responsible for the manuscript and proofs. This is the person to whom all correspondence and reprints will be sent. The corresponding author is responsible for keeping the editorial office updated with any change in details until the paper is published.

Abstract and Keywords

The abstract must not exceed 250 words. It should summarize the aim of the study and describe the work undertaken, results and conclusions. For Original Articles and Technical Notes, the abstract should be structured under four subheadings: **Background, Methods, Key Results and Conclusions & Inferences**. For Review Articles, the abstract should be structured under **Background and Purpose**. For Mini-review editorials, “Hot Topics” and Case Reports, the abstract should be unstructured, i.e. without the subheadings. In addition, you should list up to six keywords in alphabetical order. For ideas on optimising your abstract, see [here](#).

Key Points

The Key Points of research papers should provide readers with a concise, but precise, synopsis of the paper, and make the research accessible to readers from overlapping disciplines.

Key Points should be written clearly, in lay English that can be understood by a non-expert in the area, and the use of scientific language should be kept to a minimum. Only those abbreviations in common usage will be allowed.

The Key Points summary should be written in short sentences, should not exceed 80 words total, and should be presented as 3 bulleted points as follows:

- The first point should describe, in one or two short sentences, the state of current knowledge and the key question(s) being addressed in the research paper
- The second point should describe the results of the current paper. It is neither appropriate nor necessary to provide numerical results or statistical details
- The third point should state the importance of these results in the context of the broader field of neurogastroenterology and motility, in health and disease.

Introduction

This section should not exceed more than 500 words and should not have a separate heading. The Introduction should briefly discuss the objectives of the study and provide the background information to explain why the study was undertaken, and what hypotheses were tested.

Materials and methods

Animal preparation and experimentation should cite the approving governing body. Equipment and apparatus should cite the make and model number and the company name and address (town, state/city, country) at first mention.

Give all measurements in metric units and use negative indexing (mg mL^{-1} , not mg/mL). Use generic names of drugs. Symbols, units and abbreviations should be expressed as Système International (SI) units. In exceptional circumstances, others may be used, provided they are consistent. If necessary, please contact the editorial office for further advice.

Results

Tables and text should not duplicate each other.

Discussion

This section should not exceed more than 1500 words and should be concise. The Discussion should include a brief statement of the principal findings, a discussion of the validity of the observations, a discussion of the findings in light of other published work dealing with the same or closely related subjects, and a statement of the possible significance of the work. Authors are encouraged to conclude with a brief paragraph that highlights the main findings of the study.

Acknowledgments, Funding, and Disclosures

It is the duty of authors to acknowledge funding sources, technical assistance, provision of materials or reagents and other matters that relevant to the paper. Authors must acknowledge individuals who do not qualify as authors but who contributed to the research. If the work was sponsored by an organization, charity or industry, it is essential this be declared and, in the case of industry-sponsored research, the authors need to indicate that they had complete access to the data that supports the publication. If the paper was written by a professional medical writer, this must be disclosed and follow the [Ethical Policies of Neurogastroenterology & Motility](#).

The Journal insists that authors disclose their contributions to the work described in the submitted manuscript. Some examples include:

- AB performed the research
- CD designed the research study
- EF contributed essential reagents or tools
- GH analyzed the data
- IJ wrote the paper.

An author may list more than one contribution, and more than one author may have contributed to the same element of the work.

Example:

- AB performed the research; AB & CD analyzed the data and wrote the paper; EF contributed the knockout mice for the study and GH designed the research study and wrote the paper.

All sources of funding must be disclosed clearly and in full via a Funding Statement. This statement will be published in the Funding section of the paper (please see further information on NIH funding below). List governmental, industrial, charitable, philanthropic and/or personal sources of funding used for the studies described in the manuscript. Attribution of these funding sources is preferred. Please indicate "No funding declared" if no funding is associated with the paper.

Examples:

- This work was supported by a grant from the National Institutes of Health, USA (DKxxxx to AB).
- This work was supported by the Crohn's and Colitis Foundation of Canada (grant to AB and CD).
- This work was supported by a grant from Big Pharma Inc. (to AB) and equipment was donated by Small Pharma Inc. EF received a graduate studentship award from the University of xxxxx.

The Journal insists on full disclosure of competing financial and other interests from all authors. This is mandatory and a condition of publication. At the end of the acknowledgments section, there must to be a statement of these interests or the following statement: "No competing interests declared". Authors are also required to submit a [Conflicts of Interests \(COI\)](#) form upon acceptance (see Supporting Documents).

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. Sample references follow:

Journal article:

1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. *J Comp Neurol* 1998;390:537-551.

Book:

2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.
Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.

For more information about AMA reference style - [AMA Manual of Style](#).

Abbreviations

Include in the manuscript a list of new or special abbreviations along with the spelled out form or definition. For commonly accepted abbreviations, word usage, symbols, etc., authors are referred to the CBE Style Manual published by the American Institute of Biological Sciences or Units, Symbols and Abbreviations published by the Royal Society of Medicine. The abbreviations should be derived from the American spelling convention [e.g. 'TLESR' (American: esophagus), not 'TLOSR' (British: oesophagus)].

Tables

Tables should be numbered consecutively within the text. Tables and text should not duplicate each other. If possible, hold tables to one standard manuscript page; if the table continues past one page, repeat all column headings and the stub (left-hand column). Explain all abbreviations in a footnote. Provide a number and title for each table. Regardless of authorship or publisher, permission must be received in writing for its use if a table has been previously published. Include an acknowledgment of the original source in a footnote. Tables should not be submitted as photographs or graphics files.

Figures

Labelling should be in 8pt Helvetica or Arial. Figure sections should be designated with upper case letters. Magnification (scale) bars should be given on electron and light micrographs. Details of the magnification bar should be noted in the figure legends. Guidance on the preparation and submission of figures, links to useful websites and access to both the Wiley house and journal-specific style guides can be found at <http://authorservices.wiley.com/bauthor/author.asp>.

Manipulation of images

The Journal follows the guidelines and procedures established by the Council of Science Editors for digital imaging data. Please note the following in particular:

- Images cannot be modified to change the overall appearance or appearance of any specific feature.
- Adjustments of brightness and contrast or colour balance are acceptable but must be applied to the entire image.
- Features cannot be obscured and any rearrangements must be explicitly indicated by the insertion of dividing lines.
- Images will be examined for any indication of improper modifications. The final acceptance of all manuscripts is contingent on any concerns raised in our review of the figures being resolved.

Figure and table legends

Cite all tables and figures in the text, numbering them sequentially as they are cited. Each figure must have a corresponding legend. The legend must be numbered with an Arabic number that corresponds to the illustration as it appears in the text. Each should begin with a short title for the figure. Legends to tables (where necessary) and figures should contain sufficient information to be understood without reference to the text. Explain all symbols, arrows, numbers, or letters used in the figure and provide information on scale and/or magnification. For photomicrographs, include information on the method of staining or preparation.

Supporting Information

Quantitative or qualitative data too extensive for inclusion in the regular edition of the Journal may be presented as supporting information. It must be included as part of the original

submission and will be reviewed as an integral part of the paper. The availability of supporting information should be indicated in the main manuscript, to appear after the references at the end of the paper, providing titles of figures, tables, etc. formatted as if the material was to appear in the print edition. We welcome audio and video material, if relevant to your paper. Full details on how to submit supporting information, including videos, can be found at <http://authorservices.wiley.com/bauthor/suppmat.asp>.

SUPPORTING DOCUMENTS

The Conflict of Interests (COI) form must accompany your accepted manuscript and is a condition of publication. It is available for download from the *Neurogastroenterology & Motility* submission site at <http://mc.manuscriptcentral.com/nmo>. It can either be uploaded as a supporting document to your manuscript (preferred), or where this is not possible, e-mailed to the journal managing editor Mrs. Maggy Barber at maggy.barber@gmail.com.

Conflict of Interests (COI) Form

Authors are required to disclose financial interests (e.g. employment, significant share ownership, patent rights, consultancy, research funding, etc.) in any company or institution that might benefit from their publication. All authors must provide details of any other potential competing interests of a personal nature that readers or editors might consider relevant to their publication. Upon acceptance for publication, all authors must complete the [Conflicts of Interests \(COI\)](#) form.

POST ACCEPTANCE

NIH-Funded Articles and Open Access

Authors can continue to publish in the journal safe in the knowledge that they will be compliant with the NIH mandate, which applies to all articles based on research that has been wholly or partially funded by the NIH that have been accepted for publication on or after 7 April 2008. The accepted version of these articles will be deposited into PubMed Central upon acceptance by the journal. There will be an embargo period of 12 months. The accepted version is the version that incorporates all amendments made during peer review, but prior to the publisher's copy editing and typesetting. The publisher will deposit the accepted version on the author's behalf. Authors should ensure that they **clearly** mark their research as funded by the NIH (or other funding body) via a Funding statement, which is published at the end of their article. If it is not clearly labelled as funded, this could affect the archiving process.

Online

Open

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. See the full list of [terms and conditions](#).

Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website [here](#). Prior to acceptance, there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

Article Tracking

Author Services enables authors to track their article – once it has been accepted – through the production process to publication online. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. [Visit http://authorservices.wiley.com/bauthor/tracking_production.asp](http://authorservices.wiley.com/bauthor/tracking_production.asp) for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Proofs

Proofs will be available as a PDF to download from the e-proofing website. Full instructions will be sent via e-mail notification when the proof is ready for review. Adobe Acrobat Reader is required in order to read this file, which can be downloaded (free of charge) from <http://get.adobe.com/reader>.

In your absence, please arrange for a named colleague to correct on your behalf. Major alterations will be charged to the author and could delay publication.

Proofs must be returned by fax/email only to the [proof collator](#) within three days of receipt of the e-proofing notification e-mail. We will not accept proofs by snail-mail, and any late return of proofs will lead to delayed publication of your paper to avoid any delay in publication of an issue. Authors will receive one set of proofs only. Please check these carefully.

Offprints

A PDF is provided upon publication to the corresponding author. Paper offprints can be purchased upon print publication [here](#).

Archiving Policy

Unless specifically requested at submission, the publisher will dispose of all material submitted 2 months post publication.